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Abstract 
Neurological disorders and related illnesses are leading causes of disability and suffering, and are 
major health problems and economic burdens to modern society. There are currently no cures or 
satisfactory disease-modifying treatments for the majority of neurological diseases and associated 
comorbid neuropsychiatric symptoms. This is partly due to still limited knowledge of the cellular 
and molecular mechanisms underlying the etiology and progression of neurological and 
neuropsychiatric disorders. A substantial body of evidence indicates the involvement of innate or 
adaptive immune cells and the inflammatory mediators they secrete in various neurological or 
neuropsychiatric disorders. However, the precise roles that immune cells play and the underlying 
molecular mechanisms that regulate immune cell functions in these disorders remain largely 
unknown. The purpose of this thesis work is to explore the role of immune cell inflammatory 
polarization and their molecular regulatory mechanisms in neurological and comorbid anxiety 
disorders using several rodent experimental models. 
First, we discovered that microglia/macrophages in the brain and spinal cord of naïve rats are 
different from each other, in terms of their abundancy, inflammatory polarization states, and 
expression of multiple microglia/macrophage-related immune molecules. Such region-specificity 
under the steady-state condition may underlie their subsequent opposite inflammatory responses 
to peripheral nerve injury and the analgesic effect of the microglial/macrophage inhibitor 
minocycline in chronic neuropathic pain. 
Since anxiety disorders are frequently observed in patients with neurological disorders, we further 
explored the association of brain microglial inflammatory polarization with anxiety traits in mice. 
We characterized microglia in the brains of four inbred mouse strains (C57BL/6J, FVB/N, 
DBA/2J, and 129S2/Sv) and discovered a strong positive correlation between brain microglial 
pro- versus anti-inflammatory (M1/M2) ratio and anxiety-like behaviors in mice. Hence, 
microglial M1/M2 ratio in the brain may be utilized as an index of anxiety or its regulatory genes 
as potential drug candidates for treating anxiety disorders. 
Finally, we discovered that a cell adhesion molecule AMIGO2 is critically involved in the 
modulation of T cell and microglial/macrophage functions, particularly T-cell homing and T-
helper cell polarization. We also observed that Amigo2 knockout (AMG2KO) mice exhibited 
ameliorated EAE. We further demonstrated that Amigo2-deficiency in T-helper cells promoted 
Akt activation and NF-kB and NFAT1 transcriptional activities, thereby leading to elevated T-
bet and GATA-3, resulted in increased IFN-?? ???? ??-10 but decreased IL-17A productions. 
Therefore, AMIGO2 may be harnessed as a potential diagnostic and therapeutic target for 
multiple sclerosis. 
11 
 
Taken together, utilizing several naturally existing, surgically, or immunologically induced 
rodent experimental models for neurological and neuropsychiatric disorders, we discovered that 
inflammatory polarizations of innate and adaptive immune cells are critically involved in these 
modeled disorders. Our data suggest that disease-modifying approaches targeting inflammatory 
polarization of microglia/macrophages or molecules that regulate T-cell polarization (e.g. 
AMIGO2), may be beneficial for tackling these neurological or neuropsychiatric disorders in the 
future. 
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1. Introduction 
Neurological disorders in the central and/or peripheral nervous systems, e.g. the brain, spinal cord 
(SC) and peripheral nerves, result in conditions such as neuropathic pain and multiple sclerosis 
(MS). According to the World Health Organization, hundreds of millions of people worldwide 
suffer from various neurological disorders and associated comorbidities, such as anxiety, 
depression, and sleep disturbance (World Health Organization, 2006). These neurological 
disorders and related illnesses greatly affect both physical and mental health, compromising both 
working ability and quality of life of patients. Accordingly, neurological disorders are major 
personal, social, and economic burdens to society. 
It is well established that neuronal mechanisms are critically involved in the initiation and 
progression of neurological or neuropsychiatric disorders, and many pharmacological treatments 
targeting neuronal mechanisms can, to some extent, alleviate clinical symptoms and improve 
patient quality of life. However, for most neurological and neuropsychiatric disorders, the current 
available disease-modifying treatments exhibit low to moderate short-term efficacy, while 
frequently accompanied with strong side effects and unsatisfactory long-term efficacy. This is 
largely due to currently limited knowledge of the cellular and molecular mechanisms underlying 
the development and maintenance of these neurological and neuropsychiatric disorders. 
During the past decades, in addition to an improved understanding of neuronal contribution, a 
growing body of evidence suggests the involvement of innate or adaptive immune cells (e.g. 
microglia, macrophages and T cells) and the inflammatory mediators that these cells release, in 
various neurological and neuropsychiatric disorders. However, the precise roles that these 
immune cells play in neurological and neuropsychiatric disorders remain largely unknown. 
Furthermore, the molecular mechanisms that modulate the function of these immune cells are 
even less clear. 
In terms of inflammatory properties, microglia/macrophages and T cells are known as the most 
potent yet versatile cell types in the immune system. In response to subtle changes in their 
residing microenvironment, these cells can rapidly change their morphological (ramified and 
amoeboid) or inflammatory (classical pro- and alternative anti-inflammatory polarization) status, 
or both. In an effort to restore immune homeostasis, these cells may also release various 
inflammatory mediators and in some circumstances seek help by recruiting other immune cells 
to combat foreign pathogens or tissue injuries. As the largest immune-privileged organ, the 
central nervous system (CNS) represents the most challenging environment for maintaining such 
homeostasis in diseased conditions. 
In this thesis work, we used several rodent experimental models to investigate the roles of 
microglial/macrophage polarization or AMIGO2-mediated T-cell polarization in neurological 
13 
 
and neuropsychiatric disorders including neuropathic pain, MS, and anxiety disorder. We 
characterized the temporal-spatial roles of microglia/macrophages in the brain and SC and their 
contributing roles to the analgesic effects of minocycline at different stages following spared 
nerve injuries (SNI) in rats. Furthermore, we explored the association of microglial inflammatory 
polarization in the brain with anxiety-like behaviors using four inbred mouse strains with 
differential anxiety traits. Finally, with an Amigo2-knockout (AMG2KO) mouse line, we 
systemically studied the role of AMIGO2 in modulating T-cell and microglial/macrophage 
functions, particularly T-cell accumulation and pro- versus anti-inflammatory polarization of T 
helper (Th) cells, and its involvement in acute experimental autoimmune encephalomyelitis 
(EAE).  
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2. Review of the literature 
2.1. Neuropathic pain 
2.1.1. Overview of neuropathic pain 
Acute nociceptive pain is regarded as a highly conserved and adaptive physiological response to 
external noxious stimuli such that the whole body is alerted and generates appropriate reactions 
to prevent or limit further damage or injury. However, in certain conditions, such as disease or 
severe injury, the evoked pain hypersensitivity is unable to return to normal over a protracted 
time and subsequently progresses into chronic pathological pain. 
Among various types of chronic pain, neuropathic pain is the most severe. It is a complex chronic 
pain state caused by injuries or diseases of the central (brain and SC) or peripheral nervous 
system. This results in dysfunction of the somatosensory nervous system, ranging from primary 
nociceptive afferent axons, dorsal root ganglion (DRG), dorsal horn, spinothalamic tract, and up 
to the supraspinal brain regions (e.g. the brain stem and thalamus) (Benarroch, 2010). In the 
European population, the prevalence of neuropathic pain was estimated to be 7-8% and 5% might 
suffer from severe pain symptoms (Bouhassira et al., 2008). 
With regard to its etiology, diverse conditions can result in the generation of neuropathic pain. 
Common causes include cancer, diabetes, herpes zoster and human immunodeficiency virus  
infection, SC injury, stroke, MS, or as a side effect of cancer chemotherapy or human 
immunodeficiency virus treatment (Alexander et al., 2014). Clinically, most cases of neuropathic 
pain are chronic and difficult to treat, and patients frequently develop multiple comorbidities such 
as anxiety, depression, and sleep disturbance (Scadding and Koltzenburg, 2006), which further 
contribute to or exacerbate pain sensations (Nicholson and Verma, 2004; Page et al., 2014). 
Neuropathic pain and associated comorbidities greatly affect working ability and quality of life, 
and are major health problems in society. Based on the Grading of Recommendations 
Assessment, Development, and Evaluation, tricyclic antidepressants, anticonvulsants 
(gabapentin and pregabalin), and serotonin-norepinephrine reuptake inhibitor (SNRI) 
antidepressants are strongly recommended as the first-line treatments. Lidocaine patches, 
capsaicin patches and tramadol are second-line therapies, while botulinum toxin A and opioids 
are third-line therapies for neuropathic pain (Finnerup et al., 2015; Gilron et al., 2015). However, 
these therapies lack satisfactory long-term efficacies and often have many side effects or safety 
issues. For instance, tricyclic antidepressants are generally effective in relieving neuropathic pain 
but may cause blurred vision, constipation, dizziness and stomach upset, and present safety issues 
for people with heart problems. Compared to tricyclic antidepressants, SNRI antidepressants are 
much safer and have fewer side effects, but are not as effective for pain relief. Painkillers, 
particularly opioids, are robust and effective but have strong side effects (e.g. constipation, 
sedation, and stomach upset). Other topical treatments, such as lidocaine patches, are also 
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effective, but work the best primarily with localized pain (http://www.webmd.com/pain-
management/). Such unsatisfactory drug effects are largely due to the currently limited 
knowledge on how neuropathic pain is initiated and maintained. 
2.1.2. Spared nerve injury (SNI) model 
To gain insight into the cellular and molecular mechanisms underlying the development and 
maintenance of neuropathic pain and its comorbidities, a variety of rodent experimental models 
have been developed. Among these rodent experimental models, the most commonly used are 
peripheral nerve injury models, including SNI, spinal nerve ligation, chronic nerve constriction 
injury and spinal nerve lesions adjacent to the DRG (Campbell and Meyer, 2006). Several 
advantages have facilitated the wide usage of these sciatic nerve injury models in preclinical 
studies of neuropathic pain. First, the surgical procedures are invasive but easy to execute. 
Second, the injuries induce reliable, robust, and persistent neuropathic pain-like mechanical 
hypersensitivity that can be easily measured by the classical von Frey hair test. Finally, only the 
ipsilateral side of an operated rodent is affected following nerve injuries, and hence the 
contralateral side may be used as an internal control for experimental purposes (Alexander et al., 
2014). 
2.1.3. Neuropathology in neuropathic pain 
With the help of these rodent experimental models, it is now widely appreciated that neuronal 
mechanisms play a crucial role in central sensitization following peripheral nerve injuries. 
Current knowledge suggests that after a peripheral nerve injury, a series of changes in nociceptors 
expressed by DRG neurons take place, such as upregulation of voltage-gated sodium channels 
and transient receptor potential channels, which result in a reduced threshold of DRG neuronal 
activation. Repetitive firing of DRG projection neurons triggers the release of multiple signals, 
including adenosine triphosphate (ATP), brain-derived neurotrophic factor (BDNF), cysteine-
cysteine chemokine ligand (CCL)2, L-glutamate and substance P (Benarroch, 2010). These 
signals then bind to their respective receptors that are expressed on the surface of spinal dorsal 
horn (SDH) projection neurons (e.g. ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, 
glutamate, neurokinin-1, and N-methyl-D-aspartate receptors), leading to their activation. 
Receptor activation could, for instance, reverse the effects of gamma-aminobutyric acid 
(GABA)A receptors from inhibitory to excitatory, and thereby triggers SDH neuronal 
depolarization, calcium influx, and a series of downstream cell signaling events, leading to 
increased excitability of SDH projection neurons and supraspinal pain sensation (Fig. 1) 
(Benarroch, 2010). 
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Figure 1. Neuron-glial interaction in neuropathic pain. Schematic diagram illustrates the crosstalk 
between neurons, microglia, and astrocytes following a peripheral nerve injury (Benarroch, 2010). 
Reprinted with permission of Wolters Kluwer Health, Inc via Copyright Clearance Center. 
 
2.1.4. Role of infiltrating peripheral immune cells in neuropathic pain 
In addition to the well-known neuronal mechanisms, peripheral immune cells that infiltrate in the 
proximity of the peripheral nerve, or into the DRG or SDH are also implicated in the disease 
pathogenesis of neuropathic pain. Neutrophils were found in lesioned nerves as early as one hour 
and peaked within a day, whereas bone-marrow derived macrophages were recruited much later 
but within 24 hours and peaked in the lesioned nerve at around 1-4 weeks following a peripheral 
nerve injury (Myers et al., 1996; Perkins and Tracey, 2000). Infiltrating neutrophils and 
macrophages release highly proalgesic pro-inflammatory substances, including cytokines, 
reactive oxygen species, and prostaglandins. Pharmacological treatment that suppresses immune 
responses or depletes circulating neutrophils or macrophages significantly impaired the 
infiltration of immune cells, reduced axonal degeneration, and attenuated neuropathic pain-like 
hyperalgesia (Barclay et al., 2007; Bennett, 1999; Clatworthy et al., 1995; Liu et al., 2000; 
Perkins and Tracey, 2000), demonstrating a critical contribution from peripheral infiltrating 
innate immune cells. 
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Besides innate immune cells, infiltrating T cells also contribute to neuropathic pain-like 
mechanical hypersensitivity in rodents. It was reported that T cells were present in the SDH of 
rats at one week after SNI and T cell-deficient recombination activating gene 1 (Rag1)-null mice 
developed less severe neuropathic pain-like mechanical allodynia (Costigan et al., 2009). 
Similarly, another study demonstrated a contributing role of spinal infiltrating CD4+ but not CD8+ 
T cells in the maintenance of neuropathic pain-like mechanical hypersensitivity (Cao and DeLeo, 
2008). CD4+ T cells (also called as Th cells) can be divided into functionally distinct subtypes, 
such as Th1, Th2 and Th17 (Zhou et al., 2009). Of these subtypes, both Th1 and Th17 cells have 
demonstrated importance in neuropathic hypersensitivity (Costigan et al., 2009; Moalem et al., 
2004). Th1 cells are the main cell source for production of interferon (IFN)-? (Schoenborn and 
Wilson, 2007; Schroder et al., 2004), which activates ???????????????????????, and inhibition of 
the IFN-??????????????????????????????????????????????????????????????????????? (Tsuda et al., 
2009). Th17 cells predominantly release interleukin (IL)-17A, which is expressed by T cells 
infiltrating into injured nerve and plays a role in the recruitment, activation, and migration of 
neutrophils (Chen and O'Shea, 2008; Kleinschnitz et al., 2006; Weaver et al., 2006). More 
recently, Sorge et al discovered that instead of using a microglia-dependent pathway that is 
essential for pain perception in male mice, female mice alternatively use infiltrating T cells for 
generating neuropathic pain-like mechanical hypersensitivity (Sorge et al., 2015), suggesting that 
different pharmacological intervention strategies targeting neuroimmune mechanisms may be 
needed for treating neuropathic pain in men versus women. 
2.1.5. Microglial phenotypical plasticity 
2.1.5.1. Discovery and origin of microglia 
Microglia are one type of glial cells that are located throughout the CNS. Microglia function as 
the first-line defense against pathogens or injuries in the CNS and play an important role in 
restoring homeostasis. Microglia were originally discovered and named by a Spanish scientist 
Pio Del Rio-Hortega, one student of Santiago Ramón y Cajal, in the 1920s. After a long period 
of silence, in 1988 Hickey and Kimura demonstrated that perivascular microglia in the CNS were 
derived from the bone marrow and were fully competent antigen-presenting cells (Hickey and 
Kimura, 1988), which further supported Pio Del Rio-Hortega??????????????????????????????????
peripheral macrophages share similar functionalities in terms of antigen presentation and 
phagocytosis. Since then, microglial involvement in CNS development, aging, neurological 
disorders, and brain inflammatory diseases have been extensively studied. 
Originally thought to be derived from hematopoietic stem cells in the bone marrow, similar to 
peripheral macrophages, microglia were later revealed and are now commonly believed to 
originate from the yolk sac primitive macrophages during embryonic (E)8.5, colonize the 
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neuroepithelium, expand and occupy the whole CNS under normal conditions (Ginhoux et al., 
2010; Ginhoux et al., 2013). 
2.1.5.2. Microglial phenotypical plasticity 
In the healthy CNS, microglia are a population of highly dynamic cells as opposed to being in a 
resting state as previously assumed. They regularly scan their residing microenvironment in the 
CNS with highly motile processes and protrusions to detect subtle changes through a variety of 
receptors expressed on their cell surface. These receptors include immunoglobulin (Ig) 
superfamily receptors (e.g. triggering receptors expressed on myeloid cells and Fc? receptors), 
chemokine receptors, pattern recognition receptors (e.g. toll-like receptor (TLR)4), purinergic 
receptors, and phosphatidylserine receptors and gap junction proteins (Hu et al., 2014; 
Nimmerjahn et al., 2005). Upon detection of danger signals within the residing 
microenvironment, microglia can make rapid responses by changing their morphology, 
immunological status (pro- versus anti-inflammation), or both. Such responses depend on the 
location and function they have to fulfill in combating pathogens or injuries and restoring brain 
homeostasis. 
2.1.5.2.1. Microglial morphological plasticity 
Under physiological conditions, microglia exhibit a ramified morphology with extremely motile 
processes and protrusions (Nimmerjahn et al., 2005). Upon detection of danger signals in the 
residing microenvironment after internal or external pathological insults or injuries, microglia 
can rapidly alter their morphology from ramified to amoeboid (or phagocytic) to exert appropriate 
functions (e.g.  phagocytosis of cellular debris). However, recent studies suggest that microglial 
morphological changes are actually much more complicated than just the bi-modular ramified-
amoeboid switches, and more transitional microglial morphological phenotypes exist as proposed 
in several models (Walker et al., 2014). Notably, Hanisch and Kettenmann proposed that upon 
activation, microglia can transform into several functionally distinct morphological phenotypes. 
For example, the reactive phenotypes may transition between different phenotypes depending on 
the elimination of initial activating signals and feedback signals coming from residing 
microenvironment within the CNS (Hanisch and Kettenmann, 2007). 
2.1.5.2.2. Microglial immunological plasticity 
In terms of immunological functions such as antigen presentation and phagocytosis, microglia 
are considered rather similar to their macrophage counterparts in the peripheral immune system. 
Microglia and macrophages are regarded as the most potent innate immune cells with diverse 
immunological phenotypes, with roles in CNS tissue destruction, repair, and regeneration, 
particularly under pathological conditions (Hu et al., 2015). Similar to the pro-inflammatory M1 
versus anti-inflammatory M2 paradigm for peripheral macrophages, microglial M1/M2 
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polarization has been characterized in a variety of neurological or neuropsychiatric disorders (e.g. 
neuropathic pain, MS, and anxiety) (Franco and Fernandez-Suarez, 2015; Hu et al., 2015; Li et 
al., 2014; Miron et al., 2013; Popiolek-Barczyk et al., 2015; Xu et al., 2016). In response to subtle 
microenvironmental changes, microglia may acquire functionally distinct immune phenotypes to 
exert diverse effector functions. These immune phenotypes include classically activated M1, 
alternatively activated M2, and acquired deactivated M2 (Fig. 2) (Colton and Wilcock, 2010; 
Colton, 2009; Frank et al., 2007). 
 
Figure 2. Microglial M1/M2 paradigm and its role in neurological disorders. Schematic diagram 
illustrates different microglial polarization states including classically activated M1, alternatively activated 
M2, and acquired deactivated M2, and their distinct roles in inflammation and neurovascular network. 
 
Upon stimulation by pro-inflammatory mediators present in the residing microenvironment (e.g. 
IFN-??? lipopolysaccharide (LPS), and tumor necrosis factor (TNF)-?), microglia upregulate 
several co-stimulatory molecules, such as major histocompatibility complex class II (MHCII).  
Microglia can also secrete pro-inflammatory cytokines and mediators, such as nitric oxide and 
free radicals, thereby contributing to and exacerbating neuronal tissue damage. In contrast, 
following stimulation by anti-inflammatory substances (e.g. IL-4, IL-10, and IL-13), microglia 
can be alternatively activated by upregulating various cell surface receptors for scavenging (e.g. 
cluster of differentiation (CD)206) and phagocytosis, and secrete anti-inflammatory cytokines 
(e.g. IL-4, IL-10, and IL-13), growth factors, and neurotrophic factors. These help dampen 
inflammation, clear cell debris, and promote angiogenesis (Saijo and Glass, 2011). In addition, 
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microglia may also acquire an M2-like deactivated/quiescent state through constitutively 
expressing inhibitory cell surface receptors (e.g. CD172a, CX3CR1, and CD200R), which 
constantly receive contact-dependent signals from their respective neuronal ligands, such as 
CD47, CX3CL1, and CD200 (Carson et al., 2007; Cherry et al., 2014; Hu et al., 2014; Ransohoff 
and Cardona, 2010; Saijo and Glass, 2011). Emerging evidence suggests that microglia may 
upregulate surface expression of such receptors and thus play a neuroprotective role in multiple 
CNS diseases or injuries (Franco and Fernandez-Suarez, 2015; Hu et al., 2015). For example, 
CD172a bears an inhibitory immunoreceptor tyrosine-based inhibition motif in its cytoplasmic 
tail. It has been shown to confer an inhibitory effect on the activation of other inflammatory 
receptors (Blackbeard et al., 2007; Linnartz and Neumann, 2013). 
However, we should bear in mind that pro-inflammatory M1 and anti-inflammatory/quiescent 
M2 microglia are just two facets of a complicated activation profile, which represent a simplified 
model in understanding the immune functions of microglia. More polarization states of microglia 
exist, particularly in vivo as recently proposed (Heppner et al., 2015). As such, nowadays some 
researchers do not favor the most commonly used M1/M2 paradigm for microglia (Ransohoff, 
2016). Nonetheless, the concept of the simplified microglial M1/M2 paradigm remains as a useful 
starting point to define the detrimental or beneficial role of microglial activation and to screen 
novel pharmacological interventions that target microglia in various neurological and 
neuropsychiatric disorders. 
2.1.5.3. Microglial regional specificity 
For a rather long time, researchers have considered microglia as a homogeneous glial cell 
population throughout the CNS and therefore have mistakenly assumed that they play exactly the 
same roles regardless of their location within the CNS. Based on this misleading assumption and 
limited availability of spinal microglia, most researchers, especially those investigating spinal 
microglia (e.g. SC injury and neuropathic pain), have used brain-derived microglia as their study 
materials to understand possible involvement of spinal microglia in these disorders or injuries 
(Bronstein et al., 2013). 
Although microglia were initially shown to be differentially distributed within various brain 
regions of adult rodents (Lawson et al., 1990; Savchenko et al., 1997), it was not until recently 
that the CNS region-specific feature of microglia began to be appreciated. Several studies, 
including our own, have shown that microglia are actually very different within different CNS 
regions, in terms of their abundancy, morphology, and molecular features (Doorn et al., 2015; 
Grabert et al., 2016; Lawson et al., 1990; Li et al., 2016; Olson, 2010; Savchenko et al., 1997). 
Nevertheless, it is still unclear what biological effects such microglial regional differences may 
render on neurons and brain functions in healthy or diseased conditions. An exemplar 
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interpretation of this feature was recently suggested for aging-related brain function (Grabert et 
al., 2016). 
2.1.6. Role of microglia in neuropathic pain 
Other than infiltrating immune cells, accumulating evidence suggests that local glial cells 
substantially modulate neighboring neuronal activity, thereby contributing to neuropathic pain. 
Indeed, glial cells, astrocytes and microglia included, and neuron-glia interactions are critically 
involved in the development and maintenance of neuropathic pain (Benarroch, 2010; Grace et 
al., 2014; Graeber and Christie, 2012). 
The possible involvement of microglia in neuropathic pain was demonstrated by animal studies 
showing efficacy of pharmacological interventions (e.g. minocycline and fluorocitrate) that target 
microglia on attenuating neuropathic pain-like mechanical allodynia or hyperalgesia (Milligan 
and Watkins, 2009). Although the compounds were subsequently revealed to target other cell 
types as well (for example, in addition to microglia, minocycline inhibits macrophages and 
fluorocitrate targets astrocytes), these studies nevertheless indicate a potential involvement of 
microglia in the disease pathogenesis of neuropathic pain. 
Microglia are central sensors within the CNS and may exhibit a range of reactions following 
peripheral nerve injury in rodents. These reactions include migration, proliferation, cell body 
hypertrophy, gene expression, and changes in expression and secretion of proteins. 
Morphological changes of microglia, to some extent, are considered informative. However, the 
lack of association between microglial morphological changes and pain hypersensitivity restricts 
its utility as a useful means to evaluate the contribution of microglia to neuropathic pain 
(Alexander et al., 2014). 
Immunologically, microgliosis and microglial activation represented by upregulation of CD11b/c 
(integrin alpha M and alpha X chains) take place in early stages following peripheral nerve injury 
in rodents, accompanied by development of mechanical hypersensitivity (Echeverry et al., 2008). 
Moreover, pharmacological interventions that inhibit microglial activation are capable of 
attenuating neuropathic pain-like mechanical hypersensitivity (Ledeboer et al., 2005; 
Raghavendra et al., 2003). Based on these observations, microglial activation is mainly regarded 
as a detrimental factor in neuropathic pain. However, there is no direct experimental evidence 
supporting such a pro-inflammatory role of spinal microglia, since peripheral nerve injury-
activated spinal microglia neither express increased levels of MHCII, nor produce large amounts 
of pro-inflammatory mediators, such as cytokines and reactive oxygen species (Alexander et al., 
2014). Therefore, it is possible that instead of playing a pro-inflammatory role, spinal microglia 
alternatively exhibit neuroprotective phenotypes in neuropathic pain. 
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Mechanistically, following peripheral nerve injury, microglia can detect multiple signals released 
by pre-synaptic SDH neurons through a series of receptors expressed on the cell surface. These 
receptors include pattern recognition receptors (e.g. TLR4), chemokine receptors (e.g. C-C motif 
chemokine receptor (CCR)20, CX3C chemokine receptor 1 (CX3CR1)), and purinergic receptors 
(e.g. P2X purinoceptor 4 (P2X4), P2X7, and P2Y12) (Fig. 1). Activation of these receptors 
initiate a cascade of cell signaling events, leading to activation of nuclear factor kappa B (NF-
kB), thereby promoting transcription and synthesis of pro-inflammatory cytokines, such as IL-
???? ??-6, and TNF-??? ?????? ???-inflammatory cytokines may activate cyclic adenosine 
monophosphate (cAMP) response element-binding protein via extracellular signal-regulated 
kinase signaling pathway by binding to their receptors (e.g. IL-1R, TNFR) expressed on post-
synaptic neurons, resulting in potentiation of glutamate-mediated excitation of these neurons. 
Meanwhile, several other mediators released by microglia are also critical for neuropathic pain 
hypersensitivity. For example, Cathepsin S can cleave fractalkine and promote its release, which 
in turn further activates microglia through CX3CR1 receptors. BDNF, another mediator released 
due to microglial P2X4R activation, may act through tropomyosin receptor kinase B (TrkB) 
receptor to downregulate the expression of potassium chloride cotransporter (KCC)2 on dorsal 
horn neurons. The downregulation of KCC2 flips GABAA receptor from inhibitory to excitatory. 
Together with neuronal-derived calcium influx and the other above-mentioned signals, these cell-
signaling events result in increased excitability of SDH projection neurons and supraspinal pain 
sensation (Alexander et al., 2014; Benarroch, 2010). 
 
2.2. Multiple sclerosis (MS) 
2.2.1. Overview of MS 
MS is the most common chronic inflammatory demyelinating disease in humans. It affects around 
2.5 million people worldwide and leads to neurological and physical disability in young adults 
between the ages of 20-40, with a prevalence rate two-fold higher among women than men 
(Dendrou et al., 2015). According to the pattern of clinic progression of the disease, MS is 
subdivided into four major forms, including relapse-remitting (RRMS), progressive relapsing, 
primary progressive, and secondary progressive types. About 85% of MS patients repeatedly 
undergo relapses with partial or complete recoveries (or remissions), and hence belong to the 
RRMS type. More than half of RRMS patients may develop further into secondary progressive 
MS (Constantinescu et al., 2011). Currently, there is no cure available for MS. However, several 
disease-modifying treatments are available to lower the relapse rate and slow down the formation 
of new lesions in RRMS patients. The most commonly prescribed first-line drugs for RRMS 
patients include type I IFN-?? ???? ?????????? acetate, both of which confer versatile anti-
inflammatory, neuroprotective, and regenerative effects (Constantinescu et al., 2011). 
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Natalizumab (a monoclonal antibody directed against very late antigen-4, which is an integrin 
essential in the processes of adhesion to endothelium and extravasation by which immune cells, 
particularly T cells, penetrate into the blood-brain-barrier) and general immunosuppressants (e.g. 
mitoxantrone and azathioprine) are prescribed as second-line therapies (Constantinescu et al., 
2011). However, almost all of these medications are modestly effective accompanied with strong 
side effects, poor tolerance, or significant life-threatening risks. For instance, IFN-?? ??? 
glatiramer acetate are injected under the skin or intramuscularly, and may cause side effects such 
as injection-site reactions, flu-like symptoms, and liver damage (http://www.mayoclinic.org/). 
Although natalizumab is the most potent disease-modifying treatment, it also increases the risk 
of an opportunistic infection with latent John Cunningham virus in the brain, leading to 
progressive multifocal leukoencephalopathy (Constantinescu et al., 2011). General 
immunosupressants, such as mitoxantrone and azathioprine, generate satisfactory treatment 
efficacy for certain groups of patients with MS, but may be harmful to the heart and cause blood 
cancers (http://www.mayoclinic.org/). Therefore, a better understanding of the cellular and 
molecular mechanisms that critically contribute to the initiation and progression of MS is called 
for. 
2.2.2. Experimental autoimmune encephalomyelitis (EAE) disease model 
To understand the cellular and molecular mechanisms of MS, a variety of demyelination- and 
inflammation-induced rodent experimental models have been developed. Among them, the most 
widely used one is EAE. As a prototype for T-cell-mediated autoimmune disease model, EAE is 
a complex condition in which various immuno- and neuropathological mechanisms interact with 
each other and consequently lead to clinical manifestations of key pathological features of MS, 
namely inflammation, demyelination, gliosis, and axonal damage or loss. In addition, resolution 
of inflammation and a certain degree of spontaneous remyelination occur in both MS and EAE 
diseases. Therefore, EAE serves as an excellent rodent experimental model to recapitulate these 
pathological processes of MS. There are several different ways to induce EAE in rodents. For 
example, EAE can be induced actively by immunizing animals with myelin-specific antigens, 
such as myelin oligodendrocyte glycoprotein (MOG), myelin proteolipid protein, and myelin 
basic protein or their respective peptides, emulsified in complete Freund?s adjuvant. 
Alternatively, EAE can be passively induced by adoptive transfer of myelin-reactive T cells 
generated from donor rodents following active EAE induction (McCarthy et al., 2012). 
2.2.3. Inflammation in EAE/MS 
The fact that EAE can be induced with myelin-specific proteins or their peptides and passively 
induced by adoptive transfer of myelin-specific T cells clearly suggest that EAE is an immune-
initiated disease. In the disease pathogenesis of EAE and MS, almost all adaptive and innate 
immune cells have been found in demyelinating lesions and implicated to play a role (Fig. 3) 
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(Constantinescu et al., 2011; Lassmann et al., 2012). Following immunization with myelin-
specific antigens, dendritic cells are activated in the draining lymph nodes and present myelin 
antigens to naïve T cells. The primed T cells express and secrete multiple inflammatory factors, 
such as pro-inflammatory cytokines, which then upregulate the expression of chemokines and 
integrins, compromising the permeability of the blood-brain barrier and promoting infiltration of 
various types of immune cells. Upon encountering cognate myelin antigens in the CNS, 
infiltrating T cells are reactivated by local antigen-presenting cells (e.g. microglia), thereby 
secreting inflammatory mediators, such as CCL2, IFN-?, and macrophage inflammatory protein-
1, which further promote the recruitment of other peripheral immune cells to the site of 
inflammation. Meanwhile, microglial activation triggers astrocyte activation. Within the CNS, 
glial cells and infiltrating immune cells can produce and release various types of neurotoxic 
agents, including osteopontin, glutamate, nitric oxygen, proteases, and antibodies, which jointly 
result in axonal loss and myelin damage, followed by neurological impairment and clinical 
paralysis of experimental animals (Constantinescu et al., 2011; Fletcher et al., 2010). 
 
 
Figure 3. Roles of immune and glial cells in EAE pathogenesis. Schematic diagram illustrates the 
involvement of different immune and glial cells, as well as their interactions in the disease pathogenesis of 
EAE (Constantinescu et al., 2011). Red rectangle: outside of CNS; black rectangle: CNS; the middle line 
between the rectangles represents the blood-brain-barrier. Reprinted with permission of John Wiley and 
Sons via Copyright Clearance Center. 
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2.2.4. Role of T cells in EAE/MS 
Although the mechanisms that initiate MS remain largely unclear, EAE studies demonstrate a 
critical involvement of peripheral infiltrating T cells in mediating the pathology (Fletcher et al., 
2010). The key role of T cells in MS/EAE was further emphasized by studies showing the success 
of a pharmacological intervention (Natalizumab) that inhibits T-cell infiltration into the CNS in 
both preclinical EAE studies and treating RRMS patients (Kappos et al., 2007; Yednock et al., 
1992). 
In EAE, most of the infiltrating T cells are Th cells, which are known to exhibit versatile immune 
phenotypes. In response to subtle microenvironmental changes, naïve Th cells are activated and 
differentiate into functionally distinct Th subsets, mainly Th1, Th2, and Th17 cells, which then 
secrete Th lineage-specific cytokines to exert their respective effector functions (Fig. 4). For 
example, Th1 cells secrete pro-inflammatory cytokines, including IFN-?????-??????-6, and TNF-
???and were originally thought to be the main Th subset that drives autoimmune responses in 
EAE. However, more recently, IL-17A-producing Th17 cells were demonstrated to play a major 
pathogenic role in the development and pathogenesis of EAE. Although both Th1 and Th17 cells 
are pro-inflammatory and can induce EAE alone, it is speculated that they may play temporally 
distinct functions but in a collaborative manner in disease pathogenesis, based on the observation 
that Th1 cells infiltrate the CNS at an earlier phase while Th17 cells are recruited later to maintain 
or further promote disease development (Fletcher et al., 2010). In contrast to the pro-
inflammatory and autoimmunity-promoting roles played by Th1 and Th17 cells, Th2 cells 
alternatively secrete anti-inflammatory cytokines and mediators, such as IL-4, IL-5, IL-10, and 
IL-13, which contribute to resolution of inflammation, phagocytosis, angiogenesis, and tissue 
repair. Therefore, the balance between pro- and anti-inflammatory responses is crucial in 
determining the initiation and outcome of EAE. 
In addition to the contribution from infiltrating Th cells, CD8+ T cytotoxic (Tc) cells are also 
implicated in the pathogenesis of EAE and MS, but with mixed findings so far. Some studies 
suggest that Tc cells play a pathogenic role whereas others show that Tc cells are neuroprotective 
in EAE (Weiss et al., 2007). Other than Th and Tc cells, regulatory T (Treg) cells play a regulatory 
role in maintaining immune homeostasis during EAE. The importance of Treg cells is further 
demonstrated by the efficacy of Treg- and IL-10-promoting medications (e.g. IFN-?? ????
glatiramer acetate) in treating MS patients (Arnon and Aharoni, 2009; Dhib-Jalbut and Marks, 
2010). 
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Figure 4. Th cell differentiation and functionalities. Schematic diagram illustrates functionally distinct 
Th cell subtypes, transcription regulators, lineage-specific cytokines, and their effector functions in 
inflammation and autoimmunity. 
 
In T cell receptor (TCR)-mediated signaling pathways, hallmark lineage-specific transcriptional 
regulators, such as T-box expressed in T cells (T-bet) and GATA binding protein 3 (GATA-3), 
are critical in promoting Th-cell differentiation and respective cytokine production. However, 
detailed molecular mechanisms on how these master transcription factors are regulated in T cells 
under both physiological and inflammatory conditions are not fully understood (Lazarevic et al., 
2013; Tindemans et al., 2014). According to the literature, T cell-specific transcriptional 
regulators, including nuclear factor of activated T cells (NFAT), NF-kB, activator protein 1 (AP1) 
and signal transducer and activator of transcription (STAT) proteins, cooperate with each other 
to drive the transcription and expression of Th lineage-specific transcription factors and cytokine-
encoding genes (Hermann-Kleiter and Baier, 2010; Macian, 2005). Among NFAT family 
members, NFAT1 is the main isoform expressed by T cells (Macian et al., 2002). TCR ligation 
activates the calcium-calcineurin-NFAT pathway, thereby dephosphorylating NFAT and 
promoting its nuclear translocation. Once accomplishing its task in the nucleus, dephosphorylated 
NFAT is re-phosphorylated by maintenance kinases, such as glycogen-synthase kinase 3 (GSK-
3) and casein kinase 1, to expose nuclear export signals followed by translocation back to the 
cytosol (Macian, 2005). 
27 
 
2.2.5. Role of microglia/macrophages in EAE/MS 
Besides infiltrating T cells, macrophages are another cell type that infiltrates the CNS of EAE 
animals (Constantinescu et al., 2011). Together with infiltrating macrophages, CNS resident 
microglia play a critical role in mediating neuroinflammation in EAE and MS. Microglia and 
macrophages can present myelin antigens to infiltrating T cells, leading to their reactivation. This 
initiates a cascade of cell signaling events, leading to activation of microglia and macrophages. 
Similar to peripheral infiltrating Th cells, microglia and macrophages exhibit phenotypic 
plasticity. On one hand, these cells can secrete various types of pro-inflammatory and neurotoxic 
agents, such as glutamate, nitric oxygen, osteopontin, proteases, reactive oxygen species and 
antibodies, which jointly result in the apoptosis, oxidative damage, or both of oligodendrocytes 
and inflammation-induced neurodegeneration. On the other hand, they may secrete anti-
inflammatory, phagocytic, and neurotrophic factors to exert phagocytic and neuroprotective roles 
(Sonobe and Suzumura, 2014). 
In addition to the above-mentioned antigen-presenting, inflammatory, demyelination- and 
neurodegeneration-promoting mechanisms, activated microglia/macrophages may also be 
involved in synaptic plasticity by affecting the efficacy of excitatory and inhibitory synapses 
(Benarroch, 2013). For instance, IL-???? ?????? ??? ????????? ??? ????? ??????????
microglia/macrophages and T cells, promotes glutamatergic and suppresses GABAergic 
transmission, thereby contributing to impaired cognition and spatial learning deficits 
(Chiaravalloti and DeLuca, 2008; Dutta et al., 2006; Mandolesi et al., 2010). It is also possible 
that such a long-term potentiation-like phenomenon during immune attacks in early phases will 
instead represent a highly adaptive compensational response, which promotes functional 
recovery to counteract further clinical progression after formation of an MS lesion (Nistico et al., 
2014). 
2.2.6. Neuropathology in MS 
Inflammation plays a critical role in the pathogenesis of MS and EAE. The disease-modifying 
treatments based on the concept of immunopathogenesis have been successfully translated into 
clinical use for RRMS patients (Kappos et al., 2007). However, the currently available 
immunosuppressive therapies are largely ineffective in stopping the disease progression of 
primary and secondary progressive MS patients, even though these treatments confer effects to 
reduce inflammation and relapses (Constantinescu et al., 2011). These observations suggest that 
in addition to inflammatory mechanisms, neuropathological mechanisms may also contribute to 
the disease progression of MS, particularly in progressive MS patients (Lassmann et al., 2012; 
Stadelmann, 2011). It was shown that in a subset of MS patients, oligodendrocyte apoptosis was 
the earliest structural change found in all newly forming lesions, with pronounced microglial 
activation and absence of infiltrating lymphocytes and phagocytes (Matute and Perez-Cerda, 
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2005). This phenomenon was also found in early RRMS patients in another study (Lucchinetti et 
al., 2000). Oligodendrocyte apoptosis may be triggered by viral infection (such as human 
endogenous retrovirus type W (HERV-W)), enhanced extracellular glutamate levels, or other 
signals produced during hypoxia and oxidative stress (Matute and Perez-Cerda, 2005). Besides 
oligodendrocyte and myelin damage, emerging evidence suggests that mitochondrial dysfunction 
is crucial in driving axonal degeneration, thereby contributing to the neurodegenerative processes 
in MS. Following demyelination, the intra-axonal Na+ concentration is increased due to 
enrichment of Na+ channels present on axons. Consequently, a greater energy supply and thus 
more mitochondrial content are required to remove excess intra-axonal Na+ by the Na+/K+ 
ATPase. However, due to cortical pathology or inflammatory damage, the Na+/K+ ATPase and 
ATP supply are compromised. Increased mitochondrial dysfunction accumulates and this 
alternatively reverses axonal Na+/Ca2+ pumps, which pumps Na+ out and Ca2+ in, leading to Ca2+ 
influx. The rising axonal Ca2+ concentration triggers a cascade of cell signaling events, resulting 
in enhanced production of glutamate and reactive oxygen species, which contribute to axonal 
degeneration (Witte et al., 2014). Therefore, it is very likely that, at least in some MS patients, a 
neuropathological mechanism prevails over inflammation and plays a primary role in the disease 
initiation and progression (Su et al., 2009). 
2.2.7. Cell adhesion molecule AMIGO2 
2.2.7.1. AMIGO protein family 
Cell adhesion molecules are transmembrane proteins located on the cell surface and bind to the 
extracellular matrix or other cells. These proteins are involved in a process called cell adhesion, 
which is important in many functions, such as maintaining multicellular structure, conferring 
cell-to-cell signaling and, in case of infections, facilitating pathogenic colonization. There are 
four classical families of cell adhesion molecules, including integrins, cadherins, selectins, and 
Ig superfamily. 
Amphoterin-induced gene and open reading frame (Amigo)1 was originally found to be induced 
transcriptionally in primary rat hippocampal neurons upon stimulation by neurite-promoting 
protein amphoterin (also known as high motility group box 1) (Kuja-Panula et al., 2003). 
Together with two other gene homologues, Amigo2 and Amigo3, these three AMIGOs constitute 
a novel family of type I transmembrane proteins, which contain six leucine-rich repeat (LRR)s 
and one Ig-like domain in their extracellular amino terminus. At the amino acid level, the 
similarity between AMIGOs is about 50%. In terms of tissue distribution pattern in the adult 
mouse, Amigo1 is mainly enriched in the CNS tissues whereas Amigo2 and Amigo3 are more 
widely distributed (Kuja-Panula et al., 2003). 
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2.2.7.2. Neuronal and immune roles of AMIGO2 
AMIGO proteins simultaneously carry LRR and Ig domains in their structures and belong to 
LRRIG proteins. Through a homologous BLAST search, a total of 36 human LRRIG proteins 
were ????????????????????????????????????????? ?????????????????????? ??????????????????????
ISLRs, three LRIGs, two GPRs, two Adlicans, two Peroxidasin-like proteins, three Trk 
neurotrophin receptors, an unnamed protein AAI11068, and three AMIGOs (Homma et al., 
2009). Some LRRIG molecules are expressed exclusively in the CNS, whereas the majority of 
proteins are widely distributed (Homma et al., 2009), indicating their broad-spectrum functions 
in various cell and tissue types. Since both LRR and Ig domains are frequently found in many 
proteins with diverse functions (Williams and Barclay, 1988), LRRIG proteins carrying both 
LRR and Ig domains are thus likely involved in a wide spectrum of protein-protein interactions. 
Similar to the predominant neuronal involvement of AMIGO1 in dendritic growth and neuronal 
survival (Chen et al., 2012; Kuja-Panula et al., 2003; Peltola et al., 2011; Peltola et al., 2016; 
Zhao et al., 2014), most studies concerning AMIGO2 have also focused on its involvement in 
neuronal functions. For instance, AMIGO2 was shown to inhibit apoptosis and promote survival 
of cerebellar granule neurons (Ono et al., 2003). Moreover, AMIGO2 expression in the 
hippocampal CA2 region was demonstrated to be critical in the formation of social memory (Hitti 
and Siegelbaum, 2014). H????????????????? of AMIGO2 was suggested to be potentially 
responsible for abnormal growth and severe mental retardation in humans (Gimelli et al., 2011; 
Miyake et al., 2004). In addition to its regulatory role in neurons and associated neurological 
deficits, AMIGO2 modulates functions of endothelial cells and formation of human gastric 
adenocarcinoma (Park et al., 2015; Rabenau et al., 2004). However, emerging evidence indicates 
its possible involvement in the immune system. In one study, Amigo2 was shown to be 
differentially expressed by CD4+CD8+ double-positive, CD4+ and CD8+ single-positive 
thymocytes (Tsukumo et al., 2006). Moreover, human AMIGO2 messenger RNA (mRNA) was 
enriched in Th2 cells compared to Th0 and Th1 cells (Lund et al., 2007). These findings 
nevertheless indicate that AMIGO2 may be involved in T cell function. 
 
2.3. Anxiety as a comorbidity in neurological disorders 
2.3.1. Anxiety disorders as comorbid conditions in neurological patients 
Anxiety disorders are characterized by the feeling of stress or fear. Transient feeling of stress or 
fear is an involuntary daily biological response and is considered beneficial for human beings to 
take appropriate actions to cope with potential threats or insults, either external or internal. 
However, unresolved and prolonged feelings of anxiety may result in mental health problems. 
Anxiety disorders are the most common mental health problems in European countries, affecting 
approximately 61.5 million people with a 12-month prevalence rate of 14%. Anxiety disorders 
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and related illnesses cost European countries hundreds of billions of euros annually (Wittchen et 
al., 2011). 
The most frequently observed anxiety disorders in the general population are generalized anxiety 
disorder, panic disorder, social phobia, and obsessive-compulsive disorder. In the US population, 
the prevalence rate for generalized anxiety disorder is 3.1%, 2.7% for panic disorder, 8.7% for 
social phobia and 1.0% for obsessive-compulsive disorder (https://www.adaa.org/). In 
neurological patients, anxiety can be viewed as a symptom associated with a neurologic disorder, 
a side effect due to medical treatment, or a comorbid condition. Compared with the general 
population, the prevalence rates of anxiety disorders in patients with neurological disorders are 
even higher. For instance, approximately 38% of neuropathic pain patients developed comorbid 
anxiety in their lifetime, with generalized anxiety disorder (22.5%), panic disorder (7.6%), social 
phobia (6.1%), and obsessive compulsive disorder (1.8%) (Radat et al., 2013). In a cohort of 
patients with MS, as many as 35.7% suffered from any kind of anxiety disorder (generalized 
anxiety disorder: 18.6%; panic disorder: 10%; obsessive disorder: 8.6%) during their lifetime 
(Korostil and Feinstein, 2007). When treating neurological disorders, much effort has been placed 
in relieving neurological symptoms, without any recognition or treatment of comorbid 
conditions, such as anxiety. This is largely based on the assumption that anxiety seen in these 
neurological patients is merely a normal response to having a neurological disorder. However, if 
left untreated, comorbid anxiety disorders may significantly contribute to and exacerbate 
morbidity and mortality in patients with neurological disorders (Davies et al., 2001). Therefore, 
a better understanding of contributing cellular and molecular mechanisms in comorbid anxiety is 
warranted in order to improve current treatment strategies for patients with these conditions. 
2.3.2. Anxiety-like behaviors in mice 
To gain insight into human pathological anxiety, a variety of behavioral testing paradigms have 
been developed for assessing anxiety levels in inbred mouse strains and genetically modified 
mouse models. The most widely used classic behavioral tests for measuring anxiety-like 
behaviors in animals include the open field test (OF), elevated plus maze (EPM), and light-dark 
(LD) tests. Multiple parameters in these tests can be used as indexes of anxiety levels of an 
animal. For example, the higher percentage of time that an animal spends in the corner of an open 
field, the more anxious this animal is (Hölter et al., 2011). 
2.3.3. Critical brain regions associated with anxiety disorders 
Combining with various behavioral paradigms, imaging studies have been widely used to 
understand threat perception, fear acquisition, aversive-affect processing, and the regulation of 
these processes in both human and animal subjects (Phan, 2015). In preclinical studies using 
rodent experimental models, several key brain regions closely associated with anxiety have been 
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revealed. These brain regions include the prefrontal cortex (PFC), amygdala, and hippocampus 
(Phan, 2015). It has been suggested that these interconnected brain regions form a frontal-limbic 
circuit involving prefrontal, limbic, and paralimbic areas. However, how these interconnected 
brain regions communicate with each other, process danger cues, and ultimately produce the 
feeling of stress or fear is poorly understood. Current knowledge suggests that neurotransmitters, 
neuropeptides, and neuroendocrine hormones play a role (Phan, 2015). 
2.3.4. Role of microglia in anxiety disorders 
In rodent experimental models, previous studies have shown that both acute and chronic 
psychological stress may trigger microglia to produce pro-inflammatory cytokines in the brain, 
such as IL-??????-6, and TNF-??(Blandino et al., 2009; Frank et al., 2007; Nguyen et al., 1998; 
Tynan et al., 2010; Wohleb et al., 2012). Under physiological conditions, these cytokines may 
function as mediators that convey information from the immune to the nervous system, thereby 
exerting adaptive responses to physical or emotional stress by induction of sickness behaviors or 
disruption of emotional stress responses (Dantzer et al., 2008; Yirmiya and Goshen, 2011). 
Cytokines injected directly into brain regions may potentiate anxiety-like behaviors in rats 
(Connor et al., 1998). In fact, cytokines have been implicated in modulation of neuronal activity 
in brain regions such as the amygdala, hippocampus, hypothalamus, and cerebral cortex 
(Besedovsky and del Rey, 1996; Elenkov et al., 2000). Moreover, cytokine signaling within the 
brain has been shown to modulate several critical brain functions. These functions include 
neurotransmitter metabolism, neuroendocrine signaling, synaptic plasticity, and neural circuitry 
of mood formation (Salim et al., 2012). However, exacerbated and prolonged immune activation 
may be detrimental to memory formation, neuronal plasticity, and neurogenesis (Yirmiya and 
Goshen, 2011). It has been demonstrated that prenatal immune activation may act as an 
environmental risk factor, and, together with genetic factors, critically contribute to the 
pathogenesis of neuropsychiatric disorders. Accordingly, pharmacological treatment with the 
microglial/macrophage inhibitor minocycline can restore working memory and inhibit 
depression-like behaviors in rodents (Hinwood et al., 2013; Kreisel et al., 2013). 
In addition to direct sensation of psychosocial stressors, microglia are also responsive to 
environmental stimuli, such as peripheral immune activation, either directly or in combination 
with psychosocial stress. For example, pre-existing stress exposure sensitized LPS-induced 
cytokine production (Frank et al., 2007; Johnson et al., 2002). Neonatal infection attenuated 
corticosterone response to an acute stressor (Bilbo et al., 2005; Bilbo and Schwarz, 2012). 
Maternal immune activation in mice increased the vulnerability of their offspring to deficits in 
cognition and somatosensory gating in response to foot-shock-induced stress (Giovanoli et al., 
2013). Moreover, peripheral innate immune challenge provoked microglial activation and 
prolonged social withdrawal in socially defeated mice (Wohleb et al., 2012). Therefore, 
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microglial activation due to psychosocial stressors or environmental stimulation is critical in 
anxiety-related mental disorders. 
Besides the above-mentioned inflammatory functions, emerging evidence suggests that microglia 
may also play an important role in synaptic pruning. As such, microglial deficit impairs 
neuroplasticity and neurogenesis, therefore resulting in cognitive deficits and contributing to 
development of neuropsychiatric disorders, such as anxiety disorders (Aguzzi et al., 2013; 
Yirmiya and Goshen, 2011). Using mice lacking the chemokine receptor Cx3cr1, Zhan and 
colleagues demonstrated that a primary microglial deficit during the postnatal period resulted in 
a long-term deficit in synaptic multiplicity in adulthood, which was accompanied by weakened 
synaptic transmission, reduced functional brain connectivity, impaired social interaction, and 
increased repetitive behaviors (Zhan et al., 2014). After birth of Cx3cr1 KO mice, microglia are 
also crucial in the formation of dendritic spines, as transient loss of microglia led to increased 
dendritic spines and immature synapses, which was associated with immature brain circuitry 
(Paolicelli et al., 2011). Moreover, microglia may be directly involved in modulating the strength 
of glutamatergic synaptic transmission and plasticity in the hippocampal CA1 area under 
peripheral inflammatory conditions. This may underlie comorbid conditions, such as anxiety 
disorder and depression, as observed in patients with inflammatory diseases, neurological or 
neuropsychiatric disorders in which inflammation is involved (Riazi et al., 2015). 
However, how microglial activation influences anxiety remains largely unknown. A more 
thorough understanding of microglial activation and the molecular mechanisms involved in the 
regulation of microglial activation in these anxiety disorders will help develop better treatment 
strategies and identify novel pharmacological therapies for patients suffering from anxiety 
disorders (Bilbo and Schwarz, 2012; Meyer, 2011). 
2.3.5. Inbred mice as a rodent model for anxiety disorders 
It is known that anxiety disorders run in families, suggesting that genetic factors contribute to the 
risk of developing anxiety disorders. To identify the genes and biological pathways that are 
involved in anxiety disorders, several experimental approaches on human subjects have been 
used, including family and twin studies, linkage and association analysis, for detection of copy 
number variations and rare single nucleotide polymorphisms (Phan, 2015). 
Besides genetic contributions, environmental factors are now believed to play a substantial role 
in the development of anxiety disorders. In recent years, the interaction between genetic variants 
and environmental exposures has been a major focus in research of the etiology of anxiety 
disorders. From this point of view, inbred mice serve as an excellent rodent model for such 
purposes. Firstly, various inbred mouse strains differ significantly from each other in their 
anxiety-related endophenotypes concerning their locomotor activities, stress responses, learning 
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skills, and drug responses (Hovatta and Barlow, 2008; Wahlsten et al., 2006). Secondly, inbred 
mouse strains have distinct but stable genetic backgrounds with remarkably rich publicly 
available information (Li et al., 2014). Hence, inbred mice provide an excellent experimental tool 
to study how genetic disposition and peripheral or central immune activation may jointly affect 
microglial activation and development of anxiety-like behaviors in these animals. In fact, several 
high-anxiety mouse strains such as DBA/2, 129S1 and BALB/c (in contrast to low-anxiety mouse 
strains such as C57BL/6J) have been used for genetic, behavioral, and pharmacological research 
to identify target genes for diagnostic and therapeutic purposes in human anxiety disorders 
(Hovatta et al., 2005; Sokolowska and Hovatta, 2013). 
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3. Aims of the study 
The aim of this thesis work was to investigate the role of pro- versus anti-inflammatory 
polarizations of microglia/macrophages or AMIGO2-mediated T cells in neurological and 
neuropsychiatric disorders using several rodent experimental models. 
My specific objectives were: 
1) To characterize temporal-spatial profiles of microglia/macrophages in the brain and SC 
during the course of chronic neuropathic pain, and to unravel possible mechanism of efficacy 
(and inefficacy) of minocycline on attenuating mechanical allodynia following SNI surgery 
in rats. 
2) To explore the association of microglial inflammatory polarization in the brain with anxiety-
like behaviors in mice using four inbred mouse strains with different anxiety traits. 
3) To study the role of a cell adhesion molecule AMIGO2 in modulating T-cell and 
microglial/macrophage functions and in acute EAE using an AMG2KO mouse line. 
35 
 
4. Materials and methods 
The materials and methods used in this thesis are listed below and described in details in the 
original publications, which are referred in the text by their Roman numerals. 
4.1. Materials 
Table 1. Mouse and rat strains 
Mouse/rat strain Description Source Used in 
129S2/Sv mouse Inbred mouse strain Envigo II 
AMG2KO 
C57BL/6J mouse 
Amigo2-deficient inbred mouse strain Laboratory Animal 
Center at the 
University of 
Helsinki 
III 
C57BL/6J mouse Wild type (WT) inbred mouse strain Envigo and 
Laboratory Animal 
Center at the 
University of 
Helsinki 
II, III 
DBA/2J mouse Inbred mouse strain Envigo II 
FVB/N mouse Inbred mouse strain Envigo II 
Hannover-Wistar 
rat 
Outbred rat strain Envigo I 
Table 2. Plasmids 
Plasmids Description Source Used in 
pGL3-NF-kB NF-kB promoter-driven firefly luciferase 
reporter plasmid 
Dr. Guo at Wuhan 
University 
 
III 
pRL-TK Thymidine kinase promoter-driven renilla 
luciferase reporter plasmid 
Promega III 
signal-FLAG pIG-
Amigo2 
Full length Amigo2 CDS fused to signal 
FLAG 
Generated by Dr. 
Kuja-Panula 
III 
signal-FLAG pIG-
??????????? 
Cytoplasmid domain-deficient Amigo2 
CDS fused to signal FLAG 
Generated by Dr. 
Kuja-Panula 
III 
Table 3. Primary antibodies 
Antigen Description and clone Source Used in 
Akt Rabbit anti-mouse Akt Cell Signaling 
Technology 
III 
?-Tubulin Mouse anti-???????-Tubulin (clone B-7) Santa Cruz 
Biotechnology 
III 
?-Actin Mouse anti-mouse ?-Actin (clone AC-15) Sigma-Aldrich III 
CD11b PerCP/Cy5.5-conjugated rat anti-
mouse/human CD11b (clone M1/70) 
BioLegend II 
CD11b/c eFluor 660-conjugated mouse anti-rat 
CD11b/c (clone OX42) 
eBioscience I 
CD172a PE-conjugated mouse anti-rat CD172a 
(clone OX-41) 
BioLegend I 
CD28 Hamster anti-mouse CD28 (clone PV-1) Beckman Coulter III 
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CD206 FITC-conjugated rat anti-mouse CD206 
(clone C068C2) 
BioLegend II, III 
CD3 Hamster anti-mouse CD3 (clone 145-
2C11) 
Beckman Coulter III 
CD3 FITC-conjugated Hamster anti-mouse 
CD3 (clone 145-2C11) 
BioLegend III 
CD4 PE/Cy7-conjugated anti-mouse CD4 
(clone Gk1.5) 
BioLegend III 
CD45 PE-conjugated anti-mouse CD45 (clone 
30-F11) 
BioLegend III 
CD45 APC-conjugated rat anti-mouse CD45 
(clone 30-F11) 
BioLegend II, III 
CD45 PE-Texas Red-conjugated rat anti-mouse 
CD45 (clone I3/2.3) 
Abcam II 
CD45R PE/Cy5.5-conjugated anti-mouse CD45R 
(clone RA3-6B2) 
BioLegend III 
CD69 PE-conjugated anti-mouse CD69 (clone 
H1.2F3) 
Beckman Coulter III 
CD8 APC-conjugated anti-mouse CD8 (clone 
53-6.7) 
BioLegend III 
CD8 PerCP/Cy5.5-conjugated anti-mouse CD8 
(clone 53-6.7) 
BioLegend III 
F4/80 PE-Cy7-conjugated rat anti-mouse F4/80 
(clone BM8) 
BioLegend II, III 
GATA-3 Mouse anti-mouse GATA-3 (clone 
C17.8) 
BD Biosciences I 
Granulocyte FITC-conjugated mouse anti-rat 
Granulocyte (clone HIS48) 
eBioscience I 
Gr-1 APC-conjugated rat anti-mouse Ly-
6G/Ly-6C (Gr-1) (clone RB6-8C5) 
BioLegend II, III 
GSK-3? Rabbit anti-human GSK-3? Santa Cruz 
Biotechnology 
III 
Iba-1 Rabbit anti Iba-1 Wako I 
IFN-? Hamster anti-mouse IFN-?? (clone 
XMG1.2) 
BD Biosciences III 
IL-4 Rat anti-mouse IL-4 (clone 11B11) BD Biosciences III 
IL-12 Rat anti-mouse IL-12 (clone 15.6) BD Biosciences III 
IL-17A Alexa Fluor 647-conjugated anti-IL-17A 
(clone TC11-18H10) 
BD Biosciences III 
Lamin B Goat anti-human Lamin B1 Santa Cruz 
Biotechnology 
III 
MHCII PE conjugated rat anti-mouse I-A/I-E 
(clone M5/114.15.2) 
BioLegend II, III 
MHCII PerCP-eFluor 710-conjugated mouse 
anti-rat MHCII (clone OX17) 
eBioscience I 
NFAT1 Mouse anti-mouse NFAT1 (clone 4G6-
G5) 
Santa Cruz 
Biotechnology 
III 
phospho-Akt 
(Ser473) 
Rabbit anti-mouse phospho-Akt (Ser473) Cell Signaling 
Technology 
III 
phospho-GSK-?? Rabbit anti phospho-GSK-?????????????? 
(clone D17D2) 
Cell Signaling 
Technology 
III 
T-bet Mouse anti-mouse T-bet (clone 4B10) Santa Cruz 
Biotechnology 
III 
37 
 
Table 4. Proteins 
Protein Description Source Used in 
Avidin A tetrameric biotin-binding protein Merck Millipore III 
Concanavalin A 
(ConA) 
A lectin protein acting as a mitogen Sigma-Aldrich III 
IL-?? Recombinant mouse IL-1? R&D Systems III 
IL-4 Recombinant mouse IL-4 R&D Systems III 
IL-6 Recombinant mouse IL-6 R&D Systems III 
IL-12 Recombinant mouse IL-12 R&D Systems III 
TGF-?? Recombinant human TGF-?? R&D Systems III 
Table 5. Chemicals 
Chemical Source Used in 
CFSE Thermo Fisher Scientific III 
eFluor 670 eBioscience III 
Ionomycin Sigma-Aldrich III 
Minocycline Sigma-Aldrich I 
PMA Sigma-Aldrich III 
Propidium iodide Invitrogen III 
4.2. Methods 
Methods Used in 
Active EAE induction III 
Cell culture III 
CNS mononuclear cell isolation by Percoll gradient centrifugation II, III 
Cytoplasmic and nuclear fractionation III 
Database for Annotation, Visualization and Integrated Discovery (DAVID) functional 
annotation clustering 
I-III 
Dual-luciferase reporter assay III 
EPM II 
ELISA II 
Flow cytometry I-III 
Immunohistochemistry (IHC) I 
Intracellular cytokine staining III 
Intraperitoneal injection I-III 
Intrathecal administration I 
Intravenous injection III 
Light-dark test (LD) I, II 
Microarray data analysis I-III 
Multiplex bead-based cytokine assay III 
Open field test I, II 
Polymerase chain reaction (PCR) III 
????????????-efficiency analysis II 
Reverse transcription and RT-qPCR I-III 
RNA purification I-III 
T cell activation, proliferation and differentiation assay III 
T cell isolation III 
T cell homing assay III 
SNI surgery I 
Statistical analysis I-III 
Von Frey hair test I 
Western blotting and quantification by ImageJ III 
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The animals and main methods used are described below in details. 
Animals (I-III) 
Adult male Hannover-Wistar rats weighing 250-300 g, and 7-8-week-old male C57BL/6J, 
FVB/N, DBA/2J, and 129S2/Sv mice were purchased from Envigo (Horst, Netherlands). WT and 
AMG2KO C57BL/6J mice were routinely bred by heterozygous mating in a conventional or 
specific-pathogen-free (SPF) laboratory animal facility at the University of Helsinki (Helsinki, 
Finland). Rats were single-housed and mice were group-housed, whenever possible, in a 12 h 
light/dark cycle with food and water ad libitum. Experiment procedures were approved by the 
National Animal Experiment Board at the Regional State Administrative Agency for Southern 
Finland under licenses ESAVI/7863/04.10.07/2013 and ESAVI/706/04.10.07/2015. 
Anxiety-like behavioral tests (I-II) 
Animals were transported into an experimental room at least half an hour for adaptation prior to 
testing. 
Elevated plus maze (EPM): Test was carried out in a plus maze consisted of a central zone, two 
open arms and two arms closed by transparent Plexiglas walls. The maze was elevated above the 
floor level. An animal was released to the center of the maze and monitored for 5 min. Video-
tracking system was used to monitor travelled distance, number of entries and time spent in the 
closed and open arms. 
Light-dark box (LD): Test was carried out in an experimental arena divided by a dark insert into 
two equal compartments. Dark and light zones were connected by an open arc to allow free 
movement between the compartments. An animal was released to the light zone and allowed to 
explore the experimental chamber for 10 min. Distance travelled, number of transitions between 
compartments, and time spent in each zone were detected by infrared sensors in an activity-
monitoring system, and number of fecal boli excreted during the test were counted. 
Open field (OF): Test was performed in a round chamber with transparent walls and white floor. 
An animal was placed to the arena facing the wall, and its activity was video-tracked for 5-30 
min. Number of entries into and time spent in the central zone, as well as travelled distance, were 
detected by an activity-monitoring system. 
Chronic intrathecal minocycline treatment (I) 
Rats were implanted with intrathecal catheters (PE-10, BD) under general anesthesia with sodium 
pentobarbital (60 mg/kg body weight, i.p.). Starting from the operation day and 20 min before 
SNI surgery, one group received 50-μg intrathecal minocycline hydrochloride (Sigma-Aldrich) 
daily for two weeks whereas saline groups received the same volume of saline during the same 
period. 
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Correlational analysis (II) 
Correlation between parameters was ?????????????????????????-efficiency analysis. 
Dual-luciferase reporter assay (III) 
Full-length and cytosolic tail-truncated Amigo2 cDNAs were cloned into signal-FLAG pIG 
mammalian expression vector. Mammalian expression plasmid, together with pGL3-NF-kB 
firefly luciferase reporter (50 ng) and pRL-TK reporter (10 ng), which serves as an internal 
control for transfection efficiency, were co-transfected into 293T cells in triplicates with 
Lipofectamine 2000 (Invitrogen). After 24 h, luciferase activities were measured by the Dual-
Luciferase Assay System (Promega). Results are presented as relative activity of the NF-kB-
driven firefly luciferase to that of the renilla luciferase. 
EAE induction (III) 
EAE was induced by immunizing 10-week-old female mice with subcutaneous injections of 
MOG35-55 emulsified in complete Freund?s adjuvant (CFA) at two sites, followed by 
intraperitoneally administration of two doses of pertussis toxin (400 ng per dose) dissolved in 
PBS on the same and the following day of immunization, using the Hooke Kit MOG35-55/CFA 
Emulsion PTX (cat. No. EK-2110, Hooke Laboratories). Starting from 7 days post-immunization 
(dpi), mice were scored daily by at least two investigators for clinical signs of paralysis. The 
scoring criteria used were as follows: 0, no clinical signs; 0.5, partially limp tail; 1, paralyzed tail; 
1.5, paralyzed tail and one hind limb paresis; 2, uncoordinated movement and hind limb paresis; 
2.5, paralysis of one hind limb; 3, complete paralysis of both hind limbs; 3.5, complete paralysis 
of hind limb and weakness in forelimbs; 4, complete paralysis of both hind and forelimbs; and 5, 
moribound. 
Enrichment of T cells from murine spleen (III) 
Total T or Th cells were enriched from pooled spleens of adult mice using the Mouse EasySep T 
Cell Isolation Kit or the Mouse CD4+ T Cell Isolation Kit (Stem Cell Technologies). Naïve Th 
cells were enriched using the Mouse Naïve CD4+ T Cell Isolation Kit (Miltenyi Biotec). 
Flow cytometric analysis of immune cells from raw CNS tissues (I) 
Animals were anesthetized with sodium pentobarbital (Orion Pharma, Finland) and perfused 
intracardially with ice-cold PBS. Brain or spinal tissues were dissected, weighed, cut into tiny 
pieces and gently homogenized through 70-μm cell strainers (Fisher Scientific) in FACS buffer 
(PBS supplemented with 1% heat-inactivated FBS and 0.02% NaN3). Single cell suspensions 
prepared from ~25 mg tissue per sample were blocked with 5% normal rat serum, and stained 
with a combination of flow markers (Granulocyte-FITC, CD172a-PE, MHCII-PerCP-eFluor 710, 
and CD11b/c-eFluor 660) with light protection at 4°C under a 60-min continuous rotation. 
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Specificities of flow markers were confirmed by comparing with respective isotype controls. 
After washing, cells were resuspended into 2 ml FACS buffer, and acquired on a 2-laser, 6-color 
Gallios cytometer (Beckman Coulter) under a live gate of CD11b/c+. Flow cytometric data were 
analyzed with the Kaluza 1.3 analysis software (Beckman Coulter). 
Flow cytometric analysis of immune cells prepared from immune organs or enriched from CNS 
tissues (II-III) 
Cells were blocked with 10% normal rat serum in PBS on ice for 30 min, followed by staining 
with anti-mouse flow markers with light protection on ice for another 30 min. After staining, cells 
were washed and resuspended into 500 μl FACS buffer. Samples were acquired with a 2-laser, 
6-color Gallios cytometer and flow cytometric data were analyzed with the Kaluza 1.3 analysis 
software. 
Immunohistochemistry (I) 
Animals were anesthetized with sodium pentobarbital and perfused intracardially with PBS 
followed by 4% paraformaldehyde (PFA) in PBS. Lumbar (L4-6) SCs were dissected and post-
fixed in 4% PFA at 4°C for overnight. After post-fixation, the SCs were transferred to 30% 
sucrose in PBS for two days of dehydration, and finally frozen in Tissuetek (Sakura) and cut into 
20-μm floating sections with a cryostat (Leica). Cryosections were blocked with 5% normal goat 
serum and permeabilized with TBST (TBS supplemented with 0.1% Tween-20) and incubated 
with a rabbit anti-Iba1 polyclonal antibody (Wako Chemical, Japan), followed by an Alexa Fluor 
568-conjugated goat anti-rabbit IgG antibody (Life Technologies). Stained sections were 
mounted onto glass slides and imaged by a Zeiss Axioplan 2 microscope under the 10× magnitude 
and an Axiocam HR camera (Carl Zeiss). 
In vitro Th cell activation, proliferation and differentiation assays (III) 
In Th cell activation assay, anti-CD3 with or without anti-CD28 antibody was pre-coated into 48-
well plates (Corning) in 150 μl PBS per well at 4°C for overnight. Splenic Th cells (1 × 106) 
resuspended in 0.4 ml complete RPMI 1640 medium (Lonza) supplemented with 10% heat-
inactivated FBS, penicillin (100 U/ml), streptomycin (100 μg/ml), 2 mM L-glutamine, 0.05 mM 
2-mercaptoethanol, 10 mM HEPES, 1 × NEAA (Gibco), and 1 mM sodium pyruvate were then 
applied into the wells and cultured at 37°C in a humidified cell incubator with 5% CO2. After 24 
h, the cells were collected, washed, blocked with 10% normal rat serum, and stained with a 
combination of anti-CD69-PE, CD4-PE/Cy7, and CD45-APC antibodies on ice with light 
protection for 30 min before flow cytometry. T cell activation index is presented as the percentage 
of CD69+ Th cells among total Th cells. 
In Th cell proliferation assay, splenic Th cells were fluorescently labeled with CFSE and then 
stimulated with different concentrations of anti-CD3 antibody or ConA in 24-well plates at 37°C 
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in a humidified cell incubator with 5% CO2. After 72 h, the cells were collected, blocked with 
10% normal rat serum and stained with anti-CD4-APC antibody on ice with light protection for 
30 min. Following washing, the cells were resuspended into FACS buffer and propidium iodide 
(PI; 1:500) was added prior to flow cytometry. T cell proliferation index is presented as the 
percentage of CFSE+ dividing cells among total PI-CFSE+ live Th cells. 
In Th cell differentiation assay, naïve splenic Th cells were stimulated in 24-well plates pre-
coated with anti-CD3 (2 μg/ml) and anti-CD28 (2 μg/ml) antibodies in combination with the 
following polarizing cytokines and neutralizing antibodies: Th0, 10 μg/ml anti-IFN-?, 10 μg/ml 
anti-IL-4, and 10 μg/ml anti-IL-12; Th1, 30 ng/ml IL-12 and 10 μg/ml anti-IL-4; Th2, 30 ng/ml 
IL-4,10 μg/mL anti-IL-12 and 10 μg/mL anti-IFN-???and Th17, 1 ng/ml TGF-???????????????-
???????????????-6, 10 μg/ml anti-IFN-???????????????????-IL-4. ????????????????????????????????
modified Dulbecco medium (Sigma) supplemented with 5% heat-inactivated FBS, 2 mM L-
glutamine, 1 × NEAA, 0.05 mM 2-mercaptoethanol, penicillin (100 U/ml), and streptomycin 
(100 μg/ml) at 37°C in a humidified cell incubator with 5% CO2. After the time indicated, cells 
were collected and prepared for Western blotting (Th0, Th1, and Th2) or intracellular cytokine 
staining with anti-IL-17A-Alexa Fluor 647 (Th17) for flow cytometry. Cytokine levels in culture 
supernatants were measured using the bead-based Mouse Th1/Th2/Th17/Th22 13plex 
FlowCytomix Kit (eBioscience) with flow cytometry. 
In vivo T cell homing assay (III) 
Total T cells enriched from the spleens of adult WT and AMG2KO mice were fluorescently 
labeled with CFSE and eFluor 670, respectively. The fluorescently labeled donor T cells were 
washed and mixed (1:1), and approximately 9 × 106 cells were injected intravenously into tail 
veins of WT recipient mice. After 15 h, donor T cells that accumulated into secondary lymphoid 
??????????????????????????????????????????????????????????????????????????????????????????????
by staining with anti-CD45-PE, CD8-PerCP/Cy5.5 and CD4-PE/Cy7 antibodies with flow 
cytometry. 
Isolation of CNS leukocytes, and bone marrow cells, splenocytes and thymocytes (II-III) 
Animals were anesthetized with sodium pentobarbital or euthanized with CO2. Spleens were 
quickly dissected before intracardial perfusion was done with ice-cold PBS. Brains or SCs were 
dissected, cut into small pieces and gently homogenized through 70-μm cell strainers (Fisher 
Scientific) with plungers from 2-ml syringes in 7 ml RPMI 1640 medium supplemented with 2 
mM EDTA (pH 7.0). Afterward, 3 ml of 100% isotonic Percoll (GE Healthcare) were added into 
the brain or spinal homogenates and mixed thoroughly to make a final 30% isotonic Percoll, 
which was carefully layered on top of 70% isotonic Percoll. The gradient was then centrifuged at 
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500 × g for 30 min without brake. Leukocytes were collected from the interphase between Percoll 
layers and washed with ice-cold PBS. 
Spleens and thymuses were gently grinded through 40-μm cell strainers (Fisher Scientific) with 
plungers of 2-ml syringes, femoral and tibial bone marrow were flushed out by using 25-gauge 
needles attached to 1-ml syringes filled with PBS. The splenocytes and bone marrow cells were 
erythro-lyzed with the VersaLyse Lysing Solution (Beckman Coulter), and washed with ice-cold 
PBS. 
Leukocyte quantification in the CNS of EAE mice (III) 
At 9 dpi, mice were euthanized with CO2, perfused with ice-cold PBS, brains and SCs were 
carefully dissected, and mononuclear cells from these CNS tissues were enriched as described 
previously (Li et al., 2014). Enriched cells were blocked with 10% normal rat serum and stained 
with a combination of the following flow markers: CD3-FITC, CD4-PE/Cy7, and CD45-APC, 
or CD206-FITC, MHCII-PE, F4/80-PE/Cy7, and CD45-APC on ice with light protection for 30 
min for flow cytometry. 
LPS treatment (II) 
In LPS groups, each mouse was injected intraperitoneally with 1 mg/kg body weight of 
Escherichia coli O111:B4 LPS (Sigma-Aldrich) in PBS. Control groups received injection with 
the same volume of PBS. Naïve groups did not receive any treatment. 
MOG35-55-restimulated splenocytic recall response in vitro and multiplex bead-based cytokine 
assay (III) 
At 14 dpi, mice were euthanized with CO2 and spleens were dissected. Spleens were gently 
homogenized through 70-μm cell strainers in RPMI 1640 medium supplemented with 2% heated-
inactivated FBS and 10 mM HEPES. Splenocytes were erythro-lyzed with VersaLyse Lysing 
Solution, washed and filtered through 70-μm cell strainers again. Two million splenocytes were 
re-stimulated with 20 μg/ml MOG35-55 peptide (Hooke Laboratories) in 48-well plates at 37°C in 
a humidified cell incubator with 5% CO2. After 72 h, culture supernatants were collected and 
cytokine levels were measured using the bead-based Mouse Th1/Th2/Th17/Th22 13plex 
FlowCytomix Kit with flow cytometry. 
Neuropathic pain-like behavioral test (I) 
Animals were habituated to an experimental room one hour per day for three days. Mechanical 
sensitivity was assessed by a calibrated series of von Frey monofilaments producing forces 
ranging from 0.4 to 60 g (0.4, 1, 2, 4, 6, 8, 10, 15, 26, and 60 g, North Coast Medical Inc). During 
the test, an animal was placed on a grid and allowed to move freely inside a transparent box. The 
monofilaments below the grid were applied to a hind paw of the animal with increasing forces 
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until the animal withdrew it. Ipsilateral hind paw was stimulated for five times at each stimulus 
force with an ascending series of the monofilaments. At each stimulus force, number of 
withdrawal responses was counted, and withdrawal response rate (%) was calculated. An increase 
of the withdrawal response rate was considered to represent neuropathic pain-like mechanical 
hypersensitivity. 
SNI surgery (I) 
To induce neuropathic pain in rats, SNI model was adopted (Decosterd and Woolf, 2000). Before 
SNI surgery, a rat was anesthetized with 60 mg/kg body weight of sodium pentobarbital 
intraperitoneally. An incision was subsequently made into the skin on the lateral surface of left 
thigh, followed by a section through biceps femoris muscle to expose the sciatic nerve and its 
terminal branches: sural, common peroneal and tibial nerves. The common peroneal and tibial 
nerves were then tightly ligated with 4-0 silk and sectioned at sites distal to the ligation. 
Approximately 3-4 mm of the distal nerve stumps were then removed. The sural nerve was left 
intact without stretching. For the sham-operated rats, the sciatic nerve was exposed in the same 
manner but without ligation. To prevent post-operative pain, animals were treated with 0.01 
mg/kg body weight of buprenorphine twice daily for three days. 
Total RNA purification and RT-qPCR (I-III) 
Total RNA from tissues or cells was extracted using the GeneJET RNA Purification Kit (Thermo 
Scientific), treated with the TURBO DNA-free DNase (Ambion) to remove trace amount of 
genomic DNA, and reversely transcribed (200 ng) with the RevertAid First Strand cDNA 
Synthesis Kit (Thermo Scientific). RT-qPCR was performed by using corresponding primers and 
the Maxima SYBR Green qPCR Master Mix (Thermo Scientific) on the CFX384 Real-Time PCR 
Detection System (Bio-Rad) according ??? ??????????????? ????????????? Quantification was 
performed by normalization with house-keeping gene Actb or Gapdh, and represented as fold 
change 2-????. 
Th cell stimulation and subcellular fractionations (III) 
Avidin (20 μg/well) was coated into 24-well plates at 4°C for overnight. After blocking with 1% 
bovine serum albumin (BSA) in PBS, biotinylated anti-CD3 (315 ng/well) and anti-CD28 (200 
ng/well) antibodies were applied to the wells and incubated at room temperature for at least 3 h. 
Splenic Th cells (4~5 × 106) resuspended in 0.5 ml of complete RPMI 1640 medium were then 
added and stimulated at 37°C in a humidified cell incubator with 5% CO2 for 0, 1, and 3 h before 
cell lysis. For subcellular fractionation, splenic Th cells were firstly rested in complete RPMI 
1640 medium at 37°C for 1 h, and stimulated with PMA (50 ng/ml, Sigma-Aldrich) and 
ionomycin (Iono, 1 μg/ml, Sigma-Aldrich) at 37°C for 10 min. The cells were then pelleted and 
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washed once with ice-cold PBS. Cytoplasmic and nuclear fractions from stimulated Th cells were 
prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific). 
Western blotting (III) 
Cells were pelleted, lysed with Laemmli lysis buffer (2% SDS, 5% 2-mercaptoethanol, 10% 
glycerol, 25 mM Tris-HCl and 0.002% bromophenol blue) and boiled at 100°C for 10 min. The 
lysates were then separated on 4-15% gradient SDS-PAGE gels and transferred onto 
nitrocellulose membranes using the Trans-blot Turbo Transfer System (Bio-Rad). Blots were 
blocked with 5% non-fat milk or BSA in TBST (TBS supplemented with 0.1% Tween-20) at 
room temperature for one hour, followed by overnight incubation at 4°C with respective primary 
antibodies. The membranes were then incubated with horseradish peroxidase-conjugated 
secondary antibodies at room temperature for one hour, and finally developed with ECL (Thermo 
Scientific) or ECL Plus (GE Healthcare) substrates. The developed membranes were imaged by 
G:Box Chemi XX6 imager (Syngene). Densitometry analysis of blotting images was done by 
using the quantificational method in ImageJ. 
Statistics (I-III) 
Data were analyzed by one- or two-????????????????????????????????????????????????????????
???? ??? ????????? ???? ?????? ???-group comparison was performed with ?????????? t test (for 
parametric data) or Mann-Whitney U test (for nonparametric data). All values presented were 
means ± standard errors of mean (SEM) or standard deviations (SD). Statistical significance was 
set to p < 0.05. P values were classified as follows: * p < 0.05, ** p < 0.01, *** p < 0.001. 
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5. Results and discussion 
5.1. Role of microglia/macrophages in neuropathic pain (I) 
5.1.1. Elevated number of microglia/macrophages in the lumbar spinal cord (SC) of SNI 
rats 
Sciatic nerve injuries are the most commonly used rodent experimental models for neuropathic 
pain. To explore temporal-spatial roles that microglia/macrophages play in the CNS (the brain 
and the SC) during the course of neuropathic pain, we chose to adopt the widely used SNI model 
in rats. After surgical procedures, we first validated the development of neuropathic pain-like 
mechanical hypersensitivity by the classic Von Frey hair test and comorbid anxiety-like behavior 
by LD test in rats at different stages (post-operative day (POD)3, 6, and 20) following SNI surgery 
(I, Fig. 1). 
Among experimental approaches to study microglial responses, IHC is the most popular one as 
it retains not only morphological but also anatomic information. By utilizing IHC approaches, 
several previous studies revealed the occurrence of early microgliosis and microglial activation 
(upregulation of CD11b/c) in the SDH following a peripheral nerve injury (Blackbeard et al., 
2007; Echeverry et al., 2008). In our study, we also used IHC methods to assess the density of 
spinal microglia/macrophages by staining with the microglia/macrophage-specific antibody Iba-
1. In line with other reports, we found large focal increases of microglia/macrophages in the 
ipsilateral spinal dorsal and ventral horns of SNI rats on both POD7 and POD21 (I, Fig. 1). 
However, we should bear in mind that IHC has some disadvantages as well, such as limited 
availability of IHC antibodies and restrained capability for multiplex antibody staining on the 
same cell, and is a subjective, semi-quantitative analytical method. In this respect, flow cytometry 
has overcome the majority of these limitations and emerged as a convenient and robust technique 
with high sensitivity, efficiency, and reproducibility. Hence, we also employed a flow cytometry-
based approach to measure total numbers of microglia/macrophages and to characterize their 
inflammatory polarization states in the brain and SC. So far, the majority of previously described 
methods involve an enrichment step of CNS tissues with Percoll gradient centrifugation prior to 
analysis (Cardona et al., 2006; Li et al., 2014; Pino and Cardona, 2011). However, due to limited 
availability of tissues in a specific brain or spinal region, we developed an approach to analyze 
microglia/macrophages in small amounts of raw CNS tissue samples. After blocking with normal 
rat serum, single cell suspensions prepared from raw CNS tissues were stained with a 
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combination of anti-rat cell surface flow markers (CD11b/c, Granulocyte marker, MHCII, and 
CD172a). Using a live gate of CD11b/c+, we were able to measure the total number of 
microglia/macrophages (CD11b/c+Granulocyte- cells) and to characterize their inflammatory 
polarization states (MHCII+ and CD172a+ microglia/macrophages) in a small amount (~25 mg) 
of raw CNS tissue, such as the lumbar SC and the PFC (I, Figs. 2 and 3).  
By comparing the total number of microglia/macrophages (normalized to tissue weight) in the 
lumbar SC at different stages (POD3, 7 and 21) following SNI surgery, we found that more 
microglia/macrophages were present in the ipsilateral lumbar SC on both POD7 and POD21. In 
addition, we also noted upregulated CD11b/c expression by microglia/macrophages on POD21 
(I, Fig. 2). In agreement with previous findings using IHC, our flow cytometric data demonstrated 
the validity of our flow cytometry-based approach and that microgliosis taking place at an early 
stage persists for at least three weeks following a peripheral nerve injury (I, Fig. 2). 
5.1.2. Microglia/macrophages in the lumbar SC and PFC show opposite inflammatory 
responses to SNI 
To characterize inflammatory responses that microglia/macrophages may exert within the CNS 
during the course of neuropathic pain, we compared the inflammatory polarization states of 
microglia/macrophages at different stages following SNI surgery. Due to limited availability of 
flow markers for rats, we only used two flow markers (MHCII and CD172a) to define pro-
inflammatory M1 and anti-inflammatory M2 microglia/macrophages, respectively. We 
nevertheless considered MHCII+ microglia/macrophages more pro-inflammatory and CD172a+ 
cells more anti-inflammatory based on the known immune functions that MHCII and CD172a 
may be involved in (Linnartz and Neumann, 2013; Taylor et al., 2005). 
When comparing microglial/macrophage inflammatory profiles (MHCII+ and CD172a+ 
subtypes) in the lumbar SC at different stages (POD3, 7 and 21) following SNI surgery, we did 
not observe any differences between sham- and SNI-operated rats regarding the percentages of 
MHCII+ or CD172a+ microglia/macrophages in the early stages (POD3 and 7). However, at a late 
stage (POD21), microglia/macrophages in the lumbar SC exhibited an anti-inflammatory 
response, represented by a decreased MHCII+/CD172a+ microglia/macrophage ratio (regarded as 
an inflammatory index indicating the balance between pro- and anti-inflammatory 
microglial/macrophage subtypes) (I, Fig. 2). Further quantitative analysis revealed that most of 
the proliferating microglia/macrophages in the lumbar SC were in fact CD172a+ 
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microglia/macrophages (I, Fig. S1). In contrast to a pro-inflammatory role as speculated in the 
literatures, according to our observations the spinal microglia/macrophages exhibited an anti-
inflammatory and phagocytic phenotype in neuropathic pain. This is reasonable, considering the 
fact that microglia are guardians of the CNS and attempt to perform a neuroprotective function 
within the CNS in case of disease or injury. However, sufficient time may be required for 
microglia to achieve this goal. 
The PFC is one of supraspinal brain regions that are sensitized by ascending signals from SDH 
in neuropathic pain. In addition to the hippocampus and amygdala, PFC is also a critical brain 
region that is closely associated with anxiety. Because SNI rats were more anxious (I, Fig. 1), 
we also analyzed the inflammatory profiles of microglia/macrophage in the PFC. Similar to the 
lumbar SC, we did not find any changes in MHCII+/CD172a+ ratio of microglia/macrophage in 
the early stages following SNI (POD3 and 7). However, at a later stage (POD21) and in contrast 
to the anti-inflammatory response in the lumbar SC, microglia/macrophages in the PFC exhibited 
a strikingly different pro-inflammatory response, as represented by lower percentages of 
CD172a+ microglia/macrophages in the PFCs of SNI rats as compared to sham-treated rats (I, 
Fig. 3).  
To overcome the limitation of flow cytometry, we employed RT-qPCR methods to compare 
mRNA expression of multiple microglia/macrophage-related genes in the ipsilateral SC, 
ipsilateral DRG, and contralateral PFC of both SNI and sham-treated rats. These genes included 
the microglial/macrophage activation marker Cd68, the ??????????????????????????????(Fcgr)2b, 
the phagocytic receptor mannose receptor, C type 1 (Mrc1), complement genes (C1qb, C3, and 
C4a), pro- versus anti-inflammatory cytokines (Il1b, Il10, Tnf, and Tgfb1), and the M1/M2 
microglia/macrophage signature genes (inducible nitric oxide synthase (Nos2) and Arginase 
(Arg)1). RT-qPCR analysis further corroborated our flow cytometric data and demonstrated that 
spinal and cortical microglia/macrophages exhibited opposite inflammatory responses to SNI. 
Namely, the lumbar spinal microglia/macrophages showed an anti-inflammatory and phagocytic 
response, whereas their prefrontal cortical counterparts showed a dampened capacity to exert 
anti-inflammatory and phagocytic functions following SNI surgery (I, Fig. 4). 
Based on our observations, instead of a homogenous response to SNI, microglia/macrophages in 
the SC and PFC showed unexpected CNS region-specific inflammatory responses to a peripheral 
nerve injury. 
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5.1.3. The central nervous system (CNS) region-specific immune profiles in naïve rats 
As the finding that microglia/macrophages in the SC and PFC exhibit opposite inflammatory 
responses at a late stage following a peripheral nerve injury was intriguing, we decided to 
investigate possible mechanisms. We first considered the possibility that microglia/macrophages 
might be different in different CNS regions under steady-state conditions. To test our hypothesis, 
we compared microglial/macrophage profiles (abundancy, pro- and anti-inflammatory 
polarization states, and cell surface expression of immune markers) in the lumbar SC, thalamus 
(as a representative sub-cortical brain region) and cortex of naïve rats by flow cytometry (I, Fig. 
3 and S2). Regarding abundancy, we found that microglia/macrophages were most abundantly 
distributed in the cortex and least in the lumbar SC, with thalamus falling in between. When 
comparing their pro- versus anti-inflammatory subtypes, we found that the lumbar SC had the 
highest percentage of MHCII+ microglia/macrophages and lowest percentage of CD172a+ 
microglia/macrophages, whereas these parameters were completely reversed in the brain cortex. 
With regard to cell surface expression of immune markers, the lumbar SC expressed higher levels 
of CD11b/c and MHCII than the brain cortex. Collectively, these data support our hypothesis that 
microglial/macrophage immune profile is CNS region-specific in physiological conditions. 
In addition, we also performed bioinformatics analysis based on published transcriptomic 
datasets of different brain regions or between the brain and the SC. Interestingly, we found that 
several clusters of immune genes were differentially expressed among different CNS regions, 
which provided further support of our hypothesis that basal immune profile of 
microglia/macrophages is CNS region-specific (I, Table S2). The underlying mechanism for the 
differential immune states of brain and spinal microglia/macrophages is currently unclear. Based 
on the literatures, we speculated that intrinsic programing of microglial/macrophage 
differentiation during CNS development is region-specific, due to the residing microenvironment 
provided by neural progenitor cells, neurons, or other cell types. For instance, neuronal CD200, 
an important ligand for microglia receptor CD200R, was expressed at different levels within the 
brain (Olson, 2010). Moreover, differences in the permeability of the blood-brain-barrier versus 
blood-SC barrier were observed, due to, for example, the anatomical differences in vascular 
structure (Schnell et al., 1999), which may also be a contributing factor. 
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5.1.4. Microglial/macrophage inhibitor minocycline attenuates pain hypersensitivity in 
early stages following SNI 
Minocycline is a drug that efficiently dampens M1-type of microglia/macrophages. It has 
emerged as a potential drug candidate for treating neuropathic pain. However, preclinical studies 
on the analgesic effect of minocycline have so far given mixed results. Some studies reported that 
minocycline was able to prevent the development of but unable to reverse existing mechanical 
allodynia (Chang and Waxman, 2010; Willemen et al., 2010). Others have shown that 
prophylactic minocycline treatment failed to alleviate pain hypersensitivity (Burke et al., 2014; 
Taylor et al., 2015). To understand the role of CNS region-specific microglial/macrophage 
responses in the course of neuropathic pain, we utilized minocycline to modulate 
microglial/macrophage polarization in the SC to understand the role they play in chronic 
neuropathic pain. 
In preclinical studies of neuropathic pain, both systemic and local minocycline treatment 
regimens have been used. Considering the therapeutic relevance in clinical treatment, we first 
applied minocycline systemically by intraperitoneal injections into SNI rats starting from the 4th 
day following SNI surgery for a period of two weeks. Although minocycline was able to dampen 
pro-inflammatory activation of spinal microglia/macrophages, this treatment regimen failed to 
alleviate neuropathic pain-like mechanical allodynia (I, Fig. S4). Due to this failure, we then 
evaluated the efficacy of local and prophylactic minocycline treatment on mechanical allodynia 
and microglial/macrophage activation. Interestingly, this treatment regimen alleviated 
mechanical allodynia efficiently until POD10 but not afterwards, with the anti-allodynic effect 
being the strongest during POD1-3 (I, Fig. 5). In line with previous reports (Ledeboer et al., 2005; 
Raghavendra et al., 2003; Sung et al., 2012; Yamamoto et al., 2015), our data demonstrated the 
efficacy and inefficacy of minocycline in treating neuropathic pain by different regimens. 
When characterizing microglial/macrophage immune responses in the lumbar SC, we found that 
chronic intrathecal minocycline treatment efficiently dampened pro-inflammatory activation of 
spinal microglia/macrophages at both early (POD3) and late (POD13) stages (I, Fig. 5). In 
contrast, although minocycline treatment was able to downregulate CD11b/c expression on 
microglia/macrophages in the brain (the PFC and primary somatosensory cortex) on POD3 and 
POD13 (I, Fig. S5), it failed to dampen pro-inflammatory activation of microglia/macrophages 
(data not shown). 
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Our observations show that although intrathecal minocycline treatment exerts immediate efficacy 
on alleviating neuropathic pain-like mechanical hypersensitivity, possibly due to promoting anti-
inflammatory responses of spinal microglia/macrophages, this effect is not long-lasting despite 
its ongoing anti-inflammatory effect on spinal microglia/macrophages at later stages. We 
speculate that the inefficacy of minocycline at late stages may be due to the unresolved brain 
inflammation at chronic stages of neuropathic pain. 
In summary, we discovered that microglia/macrophages in the CNS are region-specific, in terms 
of their abundancy, inflammatory polarization states, and expression of multiple 
microglia/macrophage-related immune molecules in the physiological condition. Such CNS 
specificity of microglia/macrophages may underlie their subsequent opposite inflammatory 
responses to SNI. In addition, our data provide a possible explanation of the controversial efficacy 
(and inefficacy) of minocycline in attenuating neuropathic pain-like hypersensitivity and suggest 
that future treatment strategies targeting both spinal and brain inflammation may be more 
powerful in alleviating neuropathic pain in chronic stages. Of course this speculation warrants 
further studies in the near future. 
 
5.2. Role of microglial polarization in anxiety disorders (I&II) 
5.2.1. Anxiety as a comorbid behavior with neuropathic pain in rats 
Patients with neuropathic pain frequently develop comorbidities, such as anxiety, depression, and 
sleep disturbance (Alexander et al., 2014). Thus, we performed LD tests to assess anxiety-like 
behaviors for both SNI and sham-operated rats on POD0, 6, and 20. Compared to sham-operated 
controls, SNI rats secreted significantly larger numbers of fecal boil in the LD box within POD20 
(I, Fig. 1), suggesting a time-dependent development of anxiety-like behavior in these rats. 
5.2.2. Inbred mouse strains with differential anxiety traits have different microglial and 
macrophage subpopulations 
Microglia can be triggered by not only psychosocial stressors, but also peripheral immune 
challenge, such as pathogenic infection. Microglia also produce pro-inflammatory cytokines, 
which modulate animal?? behaviors. In terms of immune functions, microglia can be polarized to 
either a pro-inflammatory M1 or anti-inflammatory M2 state. However, evidence on the 
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association of microglial pro- versus anti-inflammatory polarization with anxiety is currently 
lacking. 
Due to rich genetic, physiological, and behavioral information of inbred mouse strains in public 
databases, we decided to use inbred mouse strains with differential anxiety traits in our studies. 
To choose mouse strains, we first explored Mouse Phenome Database and identified C57BL/6J, 
FVB/N, DBA/2J and 129S2/Sv as appropriate strains for such purposes, based on the fact that 
DBA/2J and 129S2/Sv male mice are more anxious than their C57BL/6J and FVB/N male 
counterparts. In our hands, we further validated their anxiety-like behaviors using classical 
anxiety behavioral tests including EPM, LD, and OF (II, Fig. 1). 
In flow cytometry, CD45 can be used as a marker to distinguish microglia from peripheral 
macrophages. In this study, to decipher microglial pro- versus anti-inflammatory activation, we 
used a combination of anti-mouse cell surface flow markers including CD206-FITC, MHCII-PE, 
CD11b-PE/Cy5.5, F4/80-PE/Cy7, and CD45-APC. This allowed us to specifically distinguish 
microglia (CD45loF4/80+ cells) from peripheral macrophages (CD45hiF4/80+ cells) and to analyze 
microglial subpopulations (pro-inflammatory MHCII+CD206- M1 and anti-inflammatory 
MHCII-/+CD206+ M2 microglia) in the brain (II, Fig. 2). 
Since these inbred mouse strains exhibit differential anxiety traits, we next asked whether 
microglial and macrophage profiles in their brains would be different under steady-state 
conditions. Our results revealed that although microglia did not differ in total numbers in the 
brains of these mouse strains, microglial M1/M2 ratio in a high-anxiety strain (DBA/2J) was 
higher than the other strains. Moreover, another high-anxiety mouse strain (129S2/Sv) had a 
higher MHCII+/MHCII- macrophage ratio than the other strains (II, Fig. 2). Collectively, these 
data suggest that microglia and macrophages in the brain are different between high- and low-
anxiety mouse strains and that myeloid cellular constituents may be different even among high-
anxiety strains. 
5.2.3. Microglia are more M1-polarized in high-anxiety mouse strains after a systemic 
lipopolysaccharide (LPS) challenge 
Based on the observation that brain microglia and macrophages showed some differences under 
steady-state conditions, we then subjected these inbred mouse strains to an acute intraperitoneal 
LPS challenge and examined brain microglial profiles after 15 h. As expected, all mouse strains 
had increased M1/M2 microglial ratios in their brains in response to LPS challenge. Interestingly, 
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the increase of M1/M2 microglial ratio was more pronounced in the high-anxiety strains (DBA/2J 
and 129S2/Sv) than in the low-anxiety strains (C57BL/6J and FVB/N) (II, Fig. 4). 
To examine whether LPS challenge can induce similar changes of macrophages in the peripheral 
immune organs, we compared splenic macrophages in these four inbred mouse strains. We found 
that the high-anxiety strains (DBA/2J and 129S2/Sv) had more pronounced increases of the 
M1/M2 macrophage ratio than low-anxiety strains (C57BL/6J and FVB/N) (II, Fig. 5), which is 
in line with microglial responses in the brain (II, Fig. 4). These data demonstrate that brain 
microglia and splenic macrophages exhibit synergized responses to peripheral LPS challenge and 
further suggest that M1/M2 microglial ratio in the brain may reflect anxiety trait of a mouse 
strain. 
5.2.4. High-anxiety inbred mouse strains express higher levels of pro-inflammatory 
cytokines and M1 microglia signature genes in the hypothalamus 
To corroborate our flow cytometric data, we further measured mRNA levels of pro-inflammatory 
genes, including Il1b, Il6, and Tnf, in the hypothalamus of phosphate-buffered saline (PBS)-
treated control mice, and microglial M1/M2 signature genes (Nos2 and Arg1) in the 
hypothalamus of LPS-treated mice using RT-qPCR. The hypothalamus is a brain region sensitive 
to both acute stress and peripheral LPS stimulation. We chose to measure cytokine levels in PBS-
injected control mice, because cytokine levels in naïve brains were barely detectable whereas 
their expression might be induced by a mild and transient handling stress in PBS groups. 
Compared with the low-anxiety strains (C57BL/6J and FVB/N), RT-qPCR analysis revealed that 
the high-anxiety strains (DBA/2J and 129S2/Sv) expressed higher levels of Il1b and Tnf in the 
hypothalamus. More interestingly, when comparing the mRNA levels of microglial M1 and M2 
signature genes in the hypothalamus of LPS-treated mice, we found that Nos2/Arg1 ratios were 
also higher in the high-anxiety strains (DBA/2J and 129S2/Sv) than the low-anxiety strains 
(C57BL/6J and FVB/N) (II, Fig. 6). These data provide further support that brain microglia in 
high-anxiety mouse strains are more polarized to pro-inflammatory M1 type. 
5.2.5. M1/M2 microglial ratios are correlated with anxiety-like behaviors 
?????? ??? ???? ?????? ??????????? ??? ????? ?????????? ?????????? ?????????????? ????????? ??? ????
whether M1/M2 microglial ratios in the mouse brains after a peripheral LPS challenge were 
associated with anxiety-like behaviors in inbred mice. Interestingly, the M1/M2 microglial ratio 
was negatively correlated with the number of light zone entries in the LD test and the percentage 
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of distance traveled in the center in the OF test (II, Fig. 7), demonstrating that the more anxious 
an animal is, the higher M1/M2 microglial ratio it has in the brain. 
5.2.6. Putative myeloid transcription factors and behavioral genes underlying 
differential microglial polarization profiles across inbred mouse strains 
Although both DBA/2J and 129S2/Sv are considered high-anxiety mouse strains, their innate 
immune profiles in the brain were different according to our analysis. We speculated that in 
addition to canonical pro-inflammatory cytokines, other immune mechanisms might also 
contribute to differences in the microglial activation profile. In fact, by comparing the public 
whole brain microarray data in PhenoGen Informatics (Bhave et al., 2007), we found that 
129S2/Sv mice expressed higher levels of multiple immune genes, such as Ccl8, Cd24a, Fcgr2b, 
Il12a, and Tlrs (II, Table 2). 
To better understand the underlying genetic mechanisms of anxiety-associated microglial 
activation, we performed transcriptomic profiling analysis to identify genes (r ≥ +0.95 or ≤ -0.95 
and p < 0.05) that were most significantly correlated with M1/M2 microglial ratios. These 
candidate genes were further imported into DAVID for functional annotation clustering. To our 
interest, we discovered a group of positively correlated transcription factors that are involved in 
hematopoietic development (II, Table 3). Moreover, we also found a group of behavioral genes 
that were negatively correlated with brain M1/M2 microglial ratios. These genes may also 
underlie differential microglial profiles among these inbred mouse strains. 
In summary, using a variety of experimental approaches, we discovered for the first time a 
correlation between brain microglial M1/M2 ratio and anxiety-like behavior in inbred mice, 
implying microglial M1/M2 ratio in the brain as a potential biological index of anxiety in mice 
or a useful readout when screening potential therapeutic drugs for treating anxiety disorders. 
 
5.3. AMIGO2 in regulation of immune cell functions and in 
EAE (III) 
5.3.1. Implication of AMIGO2 in the regulation of T-cell function and in EAE 
In the Amigo gene family, Amigo1 is enriched in the CNS of adult mouse whereas Amigo2 and 
Amigo3 are more widely distributed across tissues (Kuja-Panula et al., 2003). Consequently, most 
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studies concerning AMIGO1 have focused on its involvement in the regulation of neuronal 
function. Concerning AMIGO2, the situation is rather similar. Nevertheless, scanty yet 
accumulating evidence indicates that AMIGO2 may play a role in regulating T-cell function 
(Lund et al., 2007; Tsukumo et al., 2006). 
To identify immune cell population or tissue type in which Amigo2 is abundantly expressed, we 
first explored two online microarray databases (Immgen and IST Online) for gene expression 
patterns of Amigo1~3 in various murine and human tissue and cell types. Interestingly, Amigo2 
was most abundantly expressed in murine thymic CD4+ single-positive Th cells. However, we 
did not observe such a differential expression pattern of Amigo1 and Amigo3 in T cells, 
suggesting a potential role of AMIGO2 in regulation of T-cell function (III, Fig. S1). Similarly, 
AMIGO2 was most abundantly expressed in lymphocytes in the human tissue and cell types (III, 
Fig. S2). To validate such a differential expression pattern, we performed RT-qPCR analysis 
using total RNA purified from adult WT murine splenic Th cells and confirmed that Amigo2 was 
the most abundantly expressed Amigo gene in murine Th cells (III, Fig. 1). 
Since EAE is mainly a Th1- or Th17-driven autoimmune disease model, we next asked whether 
EAE might induce differential Amigo2 expression in Th cells. For this purpose, we induced acute 
EAE in WT female C57BL/6J mice, and enriched splenic Th cells at 14 dpi for RT-qPCR 
analysis. Amigo2 mRNA was dramatically downregulated in EAE-sensitized splenic Th cells 
(III, Fig. 1), indicating that AMIGO2 may be critically involved in EAE pathogenesis and its 
expression in Th cells may be subtype specific. Collectively, these data suggest a potential 
involvement of AMIGO2 in regulation of T-cell function and in acute EAE. 
To explore roles of AMIGO2 in vivo, we generated a conventional AMG2KO mouse line on the 
C57BL/6J background by replacing the full-length Amigo2 coding sequence with the human 
placental alkaline phosphatase gene. The inactivation of Amigo2 was confirmed by both PCR 
genotyping and RT-PCR with total RNA extracted from the murine spleen and thymus (III, Fig. 
1). Under both conventional and SPF housing environments, these mice developed normally 
without any obvious defects. We then asked whether Amigo2-deficiency might affect T cell 
development and maturation. Thus, we immunophenotyped T cells in the thymus and spleen of 
mice housed in both conventional and SPF environment and found a slight increase of T cells in 
the spleens of AMG2KO mice housed in conventional environment (III, Fig. 2). 
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Since AMIGO proteins share a high similarity at the amino acid level (50-55%), we then assessed 
whether Amigo2-deficiency in mice would result in any compensational expression of other 
Amigos, thereby masking the functionalities of AMIGO2. For this purpose, we measured mRNA 
levels of Amigos in the splenic Th cells by RT-qPCR. Amigo1 and Amigo3 mRNA expression 
did not change in the splenic Th cells of AMG2KO mice compared to WT (III, Fig. 1), suggesting 
no compensational expression (and probably no functional compensation) from other AMIGOs 
in the splenic Th cells of AMG2KO mice. 
5.3.2. AMIGO2 functions as an adhesion molecule for T cells 
To gain insight on the T-cell functions that AMIGO2 may be involved in, we first performed 
bioinformatics analysis to identify AMIGO2-correlated genes in human blood T cells using 
microarray data stored in IST Online. The most significantly correlated genes (p < 0.0075) were 
then imported into DAVID for functional annotation clustering. Interestingly, among the 
AMIGO2-correlated genes, several clusters of genes are involved in organization of the 
cytoskeleton and extracellular matrix, and in regulation of cell migration (III, Table S1). Based 
on these data, and because AMIGOs are cell adhesion molecules themselves, we speculated that 
AMIGO2 may mediate T-cell adhesion. 
To answer this question, we fluorescently labeled donor T cells enriched from the spleens of adult 
WT and AMG2KO mice with CFSE and eFluor 670, respectively, mixed them at a ratio of 1:1, 
and injected them intravenously into tail veins of WT recipient mice. After 15 h, we assessed the 
amounts of donor T cells (both Th and Tc) in the secondary lymphoid organs (including spleen, 
lymph nodes, ?????????????????????????????????? ???????staining with anti-mouse CD45-PE, CD8-
PerCP/Cy5.5, and CD4-PE/Cy7 antibodies for flow cytometric analysis. As expected, AMG2KO 
donor Th and Tc cells had impaired capacity to accumulate into the secondary lymphoid organs 
of recipient mice (III, Fig. 3), suggesting that AMIGO2 functions as a T-cell adhesion molecule. 
5.3.3. Amigo2-deficiency in T helper (Th) cells affects Th-cell activation, proliferation, 
and differentiation 
We then systemically studied whether and how AMIGO2 might be involved in other major T-
cell functions, including Th-cell activation, proliferation, and differentiation. For the Th-cell 
activation and proliferation assay, we enriched total Th cells from the spleens of adult mice and 
then applied appropriate stimulation, such as TCR co-stimulation (anti-CD3 with or without anti-
CD28 antibody) or mitogen (ConA). After stimulation, Amigo2-deficient Th cells were hypo-
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activated and hyper-proliferative as detected by flow cytometry (III, Fig. 4). The decrease in Th-
cell activation but increase in proliferation due to the loss of Amigo2 implies that AMG2KO Th 
cells may be less sensitive to TCR-induced cell apoptosis post-activation and are therefore more 
proliferative in response to anti-CD3 or ConA stimulation. 
To explore whether Amigo2-deficiency may affect Th-cell functional polarization, we isolated 
naïve Th cells from the spleens of adult mice and then polarized them into Th1, Th2, and Th17 
subtypes in vitro under respective polarization conditions (Th0 as a control condition for all other 
Th subtypes). After Th-cell differentiation, we quantitatively measured the protein levels of Th 
master transcription factors (T-bet for Th1 cells and GATA-3 for Th2 cells, respectively) in 
polarized Th cells by Western blotting. Interestingly, both T-bet and GATA-3 levels were 
elevated in AMG2KO Th1 and Th2 cells at 12 h and 24 h after in vitro polarization. With regard 
to Th17-cell differentiation, we performed intracellular cytokine staining with anti-IL-17A-Alexa 
Fluor 647 by flow cytometry and found that the percentage of IL-17A-producing Th cells was 
much lower in AMG2KO than WT controls (III, Fig. 4). We then measured Th-lineage cytokine 
levels in the culture supernatants at 72 h after in vitro polarization. In line with elevated T-bet 
and GATA-3 levels and decreased percentage of IL-17A-producing Th cells, AMG2KO Th cells 
secreted higher levels of IFN-?????????-??????????1, higher IL-10 under Th2, and lower IL-
17A under Th17 conditions as compared to WT controls (III, Table 1). 
5.3.4. Amigo2 knockout (AMG2KO) mice exhibit ameliorated EAE severity 
accompanied with reduced spinal T-cell accumulation 
The findings that Amigo2-deficiency led to aberrant T-cell functions, such as impaired T-cell 
accumulation into secondary lymphoid organs, hypoactivation, hyperproliferation, and skewed 
Th-cell differentiation, suggested that AMIGO2 might be involved in T-cell-mediated 
autoimmune diseases, such as EAE. We then subjected both WT and AMG2KO female mice to 
MOG35-55-induced acute EAE and evaluated the clinical severity of paralysis daily from 7 dpi. 
Compared to WT controls, AMG2KO mice developed less severe EAE during 14-20 dpi. 
To further understand EAE-related pathology in AMG2KO mice, we measured the number of 
infiltrating T cells (both Th and Tc cells) in the CNS (SC and brain) of EAE mice at 9 dpi by 
flow cytometry. In line with impaired accumulation of AMG2KO T cells into the lymphoid 
organs under steady-state conditions as previously observed, fewer Th and Tc cells infiltrated 
into the SCs of AMG2KO EAE mice compared to WT (III, Fig. 5). 
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5.3.5. Microglia/macrophages show anti-inflammatory response in the CNS of AMG2KO 
EAE mice 
As EAE is a complex inflammatory condition in which both innate and adaptive immune cells 
are critically involved in the disease pathogenesis, we further studied the potential contribution 
from innate immune cells, including microglia and macrophages, and their inflammatory 
polarization states in the CNS of AMG2KO EAE mice. The total numbers of microglia or 
macrophages were similar between genotypes. However, when comparing their pro- and anti-
inflammatory subtypes, we found that microglia in the brain, and macrophages in both the SC 
and the brain had lower M1/M2 ratios in AMG2KO EAE mice (III, Fig. S3), indicating anti-
inflammatory properties of microglia and infiltrating macrophages in the CNS of AMG2KO mice 
under EAE conditions. 
5.3.6. Anti-inflammatory response of splenocytes of AMG2KO EAE mice 
To determine whether peripheral immune cells (particularly T cells), would have similar anti-
inflammatory responses to EAE, we isolated EAE-sensitized splenocytes from WT and 
AMG2KO mice and assessed splenocytic recall responses by re-stimulating them with MOG35-55 
peptide in vitro for 72 h and measured cytokine levels thereafter using bead-based multiplex 
immunoassay. Although IFN-?-production did not show any genotypic difference, IL-10 levels 
were significantly higher in the cell culture supernatants of AMG2KO splenocytes than WT (III, 
Fig. 5), indicating an enhanced anti-inflammatory response generated by AMG2KO splenocytes. 
Although both innate and adaptive immune cells might contribute to IL-10-production, we 
speculated that this effect was mainly conferred by T cells because we did not find that splenic 
macrophages showed any genotypic differences in M1/M2 macrophage ratios under both 
physiological and EAE conditions. The existence of anti-inflammatory microglia/macrophages 
in the CNS of EAE mice but not in the peripheral immune organs of either naïve or EAE mice 
was intriguing. We speculated that residing microglia and infiltrating macrophages in the CNS 
might be indirectly educated and reprogrammed by infiltrating anti-inflammatory Th cells that 
were primed in the periphery, thus cooperating with each other to confer neuroprotective effects 
and ameliorate EAE in AMG2KO mice. 
The observations of elevated levels of IL-10 but not other canonical Th2 cytokines (IL-4, IL-5, 
and IL-13) under various experimental conditions (anti-CD3- plus anti-CD28-stimulated or Th2-
polarized Th cells, or MOG35-55 re-stimulated EAE-sensitized splenocytes) in AMG2KO mice 
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were also intriguing. It has been shown that IL-10 was more important than IL-4 in suppressing 
autoimmune Th1 responses in EAE by comparing IL-4- and IL-10-deficient or overexpressing 
mice (Bettelli et al., 1998). Besides, GATA-3 is capable of inducing directly Il10 gene expression 
independently of Il4 in Th cells (Saraiva and O'Garra, 2010; Shoemaker et al., 2006). Therefore, 
it is possible that upregulated GATA-3 due to Amigo2-deficiency induces IL-10 instead of IL-4, 
due to an unknown mechanism. Furthermore, several studies demonstrate that T-bet inhibits the 
expression of the Th17-specific transcription factor RAR-related orphan receptor gamma 
??????t, thereby resulting in suppressed Th17-cell differentiation, IL-17A production, and 
attenuated autoimmune responses (Fujiwara et al., 2007; Guo et al., 2009; Rutitzky et al., 2009). 
Elevated T-bet in AMG2KO Th cells may inhibit IL-17A production potentially ???? ????? 
suppression. Therefore, we speculate that Amigo2 inactivation reprograms differentiated Th cells 
to acquire an anti-inflammatory property with increased IL-10 (possibly via GATA-3) and 
decreased IL-17A production (possibly via T-bet-mediated ????? inhibition). 
Collectively, we demonstrated that Amigo2-deficiency impairs spinal T-cell accumulation and 
promotes anti-inflammatory innate immune responses in the CNS and peripheral immune organs, 
which may jointly contribute to ameliorated EAE severity in AMG2KO mice. 
5.3.7. Amigo2-deficiency in Th cells promotes NF-kB and NFAT1 transcriptional 
activities via Akt activation 
To understand the molecular mechanisms underlying AMIGO2-mediated regulation of T-cell 
signaling, we measured transcriptional activities of key transcription factors that are involved in 
TCR signaling, including NF-kB and NFAT1, by a dual luciferase reporter assay and a nuclear 
translocation assay. We observed that Amigo2-deficiency promoted transcriptional activities of 
NF-kB and NFAT1 (III, Fig. 6). Since Akt is a key kinase that regulates a variety of transcription 
factors, NF-kB and NFAT1 included, we further compared Akt activities between WT and 
AMG2KO Th cells under TCR co-stimulation and found that AMG2KO Th cells produced higher 
levels of phosphorylated Akt (III, Fig. 6). Taken together, these data suggest that Amigo2-
deficiency promotes transcriptional activity of NF-kB and NFAT1, which may be achieved 
through Akt activation. Our hypothesized model of AMIGO2-mediated regulation of T-cell 
function is shown (III, Fig. 6). 
In summary, using an Amigo2-deficient mouse line, we demonstrate that AMIGO2 is critically 
involved in the regulation of T-cell and microglial/macrophage functions, particularly in T-cell 
homing and inflammatory polarization of Th cells. More importantly, it has functional relevance 
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in vivo as loss of Amigo2 resulted in ameliorated EAE severity accompanied by decreased spinal 
T-cell accumulation and enhanced anti-inflammatory responses in the brain, SC, and spleen. 
Mechanistically, we demonstrated that Amigo2-deficiency in Th cells enhances Akt activation 
and upregulates NF-kB and NFAT1 transcriptional activities, probably leading to elevated levels 
of T-bet and GATA-3 (and possibly decreased leve?? ??? ???????? ????????????? ?????????? ???
increased secretion of IFN-????????-10 but decreased secretion of IL-17A. Our study thus suggest 
that AMIGO2 may be harnessed as a potential therapeutic target for treating MS.  
However, it is important to note that in this study we used a conventional Amigo2 knockout mouse 
model to explore its involvement in EAE, which is a complex condition in which a variety of 
immune- and neuropathological mechanisms are involved. Adoptive transfer EAE or a T-cell-
specific Amigo2 knockout mouse model is warranted in the future in order to exclude the potential 
contribution from neuronal-specific mechanisms that may confound our findings. 
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6. Conclusions and future perspectives 
As the most versatile immune cells in the immune system, microglia/macrophages or T cells are 
implicated in various neurological and neuropsychiatric disorders. However, their precise 
inflammatory roles and molecular mechanisms underlying their regulation in the context of these 
disorders are largely unknown. In this thesis work, we first characterized the temporal-spatial 
roles of microglia/macrophages in chronic neuropathic pain and their possible contribution to 
analgesic efficacy or inefficacy of minocycline in rats. Secondly, we explored the association of 
brain microglial pro- versus anti-inflammatory activation with anxiety-like behaviors in mice. 
Lastly, using an Amigo2-deficient mouse model, we revealed novel roles of AMIGO2 in 
regulation of T-cell and microglial/macrophage functions, as well as its importance in acute EAE. 
The main conclusions and future perspectives are as follows: 
1) Microglia/macrophages in the CNS are region-specific under steady-state conditions, in 
terms of their abundance, inflammatory polarization states, and expression of multiple 
microglia/macrophage-related immune genes. The CNS region-specificity of 
microglia/macrophages may determine their subsequent inflammatory responses to 
peripheral nerve injury and the analgesic effect of minocycline. Our data suggest that a future 
treatment strategy that targets not only spinal but also brain inflammation may be more 
powerful in alleviating chronic neuropathic pain. Importantly, our observation of a region-
specific profile of microglia/macrophages unravels its critical role in the normal brain as well 
as in neurological or neuropsychiatric disorders. 
2) Microglial M1/M2 ratios in the brain are positively correlated with anxiety-like behaviors in 
mice and rats. This suggests that brain microglial M1/M2 ratio may serve as an indicator of 
anxiety and a readout for diagnosis and screening of disease-modifying drugs for treating 
anxiety disorders or comorbid anxiety observed in various neurological patients. To unravel 
the molecular mechanisms of microglial polarization, the candidate genes found to be 
associated with microglial M1/M2 polarization should be validated with more specific 
genetic manipulation in animal models. 
3) AMIGO2 modulates the functions of T cells and microglia/macrophages, particularly T-cell 
homing and pro- versus anti-inflammatory polarization of Th cells, and contributes to disease 
pathogenesis of EAE. Mechanistically, Amigo2-deficiency in Th cells promotes Akt 
activation and NF-kB and NFAT1 transcriptional activities, resulting in elevated levels of T-
bet and GATA-3, possibly thereby leading to higher IFN-?? ???? ??-10 but lower IL-17A 
levels. Our findings suggest that AMIGO2 may be harnessed as a diagnostic and therapeutic 
target for MS. However, in this study, we used Amigo2 global KO mice and several 
cofounding factors may mask the effect size of AMIGO2-mediated T cells in EAE. 
Therefore, future work is warranted to explore more specifically the role of AMIGO2 in T 
cells by using either adoptive transfer EAE or T-cell conditional KO mice. 
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In conclusion, using several rodent experimental models, we demonstrated critical contributions 
of pro- versus anti-inflammatory polarization of microglia/macrophages or AMIGO2-mediated 
Th cells in neurological and neuropsychiatric disorders. These findings provide novel insights 
into cellular and molecular mechanisms underlying neurological and neuropsychiatric disorders. 
Moreover, inflammatory polarizations of microglia/macrophages and Th cells, as well as the 
molecules that are critically involved in the modulation of their balance, may be harnessed as 
therapeutic targets for treating neurological or neuropsychiatric disorders. 
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